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Abstract 
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that leads to 
dementia in the ageing population. A major characteristic lesion observed in AD is the 
accumulation of neurofibrillary tangles (NFT) in the affected brain regions. The main 
component of NFT is paired helical filaments (PHF), which mainly consist of 
hyperphosphorylated tau protein. Tau protein is a microtubule-associated protein and 
has the function of stabilizing and organizing axonal microtubules, which involve in 
intraneuronal transport. In AD, hyperphosphorylation of tau would cause microtubules 
to integrate into PHF-tau and eventually into NFT, thereby losing its physiological 
functions. 
Glycogen Synthase kinase 3p (GSK-3p) is one of the major kinases responsible for the 
hyperphosphorylation of tau and this enzyme has been proposed to play a major role in 
the pathogenesis of NFT. Therefore GSK-3p inhibitor has been considered as a drug 
target of AD. In order to find remedies for AD, extracts from Chinese Traditional 
Medicine (TCM) have been prepared to screen for inhibition activities against GSK-3p. 
A total of 55 TCM, which occur most frequently in Chinese Medicinal Formulas were 
selected for screening in cell cultures that mimics the hyperphosphorlation of Tau by 
co-transfection with Tau and GSK-3p cDNAs in Cos? cells. The expressed Tau was 
hyperphosphorylated by the co-expressed GSK-3p. The degree of hyperphosphorylated 
ii 
Tau was monitored by Western blot analysis after treatment of transfected cells with 
various TCM extracts. A TCM extract from Alphinia oxyphylla Fructus (AOF) showed 
positive result in reducing the extent of hyperphosphorylation of Tau. Further 
fractionation showed that the active component is likely present in the essential oil. 
The effect of cryptotanshinone (CT)，a compound from Danshen that was previously 
shown to be an acetylcholinesterase inhibitor, was tested for its efficacy to ameliorate 
scopolamine-induced spatial memory deficit in a Morris Water Maze Task (WMT). The 
mice were chronically treated with CT (10 mg/kg i.p) for 5 days and then the animals 
were subject to water maze tasks. Preliminary results showed that CT had a mild 




是細胞內的神經元纖維纏結（NFT)的累績0 N F T的主要成份是成對螺旋絲 
(PHF)，而PHF則是由過度磷酸化的 t au聚合而成�Tau蛋白是一種用於穩定及 
排列用於細胞運輸的神經細胞軸索的細胞支架。在ad中’ tau蛋白的過度磷酸 
化會使其變作PHF-tau ’再與微管一起集結成NFT ’使微管失去它的功能° 
糖原合成酶激酸—3p(GSK-3p)是一種在AD中令 t au蛋白過度磷酸化的激酶’ 
在NFT的形成擔當了重要的角色。是以（GSK-3P)抑制劑被考慮爲AD的藥物 
標記。這項硏究的一個目標就是要從傳統中藥（TCM)的粹取液中蹄選出能抑制 
G S K - 3 P的成分。 
我從傳統對抗痴呆的藥方中選出五十五種最常出現的草藥作這次舗選實驗。將tau 
與G S K - 3 P的 c D N A傳染到C 0 S - 7細胞中，造成模擬 t a u蛋白過度磷酸化的 
細胞模型：表達的GSK-3P會將同時表達的 tau碟酸化。實驗首先用中藥粹取液 
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I 
Chapter 1 Intorduction 
1.1 Alzheimer，s disease 
Alzheimer，s disease (AD) is first documented in the medical literature in 1907 by 
a German clinician Alois Alzheimer. It is a neurodegenerative disease, which causes a 
gradual loss of brain cells. It has been the most common cause of dementia and affects 
the major population of elderly, in approximately half of the population over the age of 
85. 
AD is a heterogeneous group of dementias that share common clinical symptoms. 
Symptoms of AD include progressive cognitive impairments, abnormalities of memory, 
problem solving, language, calculation, visuopatial perceptions, judgment, and behavior 
(Price and Sisoda, 1998). The areas of the brain that control memory and thinking skills 
are affected first, but as the disease progresses, cells die in other regions of the brain. 
Eventually, the person with AD will need complete care. If the individual has no other 
serious illness, the loss of brain function itself will cause death. The duration of the 
illness may often vary from 3 to 20 years. 
1.2 Histopathological features 
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The neuropathological hallmarks of AD are large neuron loss along with neuritic 
plaques and neurofibrillary tangles, preferentially located in limbic and cortical areas of 
the brain (Yankner and Bruce, 1999). 
The neuritic plaques are spherical, multicellular lesions containing extracellular deposits 
of p-amyloid (Ap) protein in fibrillar form. Neuritic plaques are surrounded by 
degenerating axons and dendrites, activated microglia, and reactive astrocytes (Selkoe, 
1999). Fibrillar Ap in the extracellular space inflicts physical or mechanical stress to 
nearby axons, triggering the neuronal reaction to injury (Vickers et al, 2000). Ap is 
produced from alternative splicing of Amyloid Precursor Protein (APP). The APP is a 
transmembrane molecule with a long extracellular portion. Under physiological 
conditions, a small amount of APP undergoes secretory cleavage of a long extracellular 
portion of the molecule by the intervention of an endoprotease called a-secretase. The 
released fragment is soluble and shows tropic effect on neurons in culture (Selkoe, 
1999). In AD, the processing of amyloid precursor protein is significantly altered. 
Increased amounts of APP are cleaved by endoproteases called p-secretase and 
y-secretase. This generates a 40-42 amino acid residue Ap (Davide et,al” 2001). 
Ap undergoes self-aggregation into Ap fibrils. Ap fibrils exert neurotoxic effect on 
inducing glucose deprivation, increasing oxidative stress, damaging cell membrane, 
- 2 -
inducing inflammation, binding to receptor and altered signal transduction resulting in 
apoptosis (Yanker and Bruce, 1996). 
Another major characteristic lesion observed in AD is the accumulation of 
intracellular neurofibrillary tangles (NFT) in the affected brain regions (Selkoe, 1991). 
NFT is developed in the pyramidal neuronal soma as filamentous inclusions and may 
extend into dendrites (Goedert,，1993). The NFT composes of paired helical filaments 
(PHF) and straight filaments. These abnormal filamentous structures contribute towards 
the formation of tangle-like inclusions in cell bodies. The abnormal filaments that 
comprise neurofibrillary pathology are highly insoluble, such that 'ghost' (released) or 
'tombstone' (like a bulb at the surface of the cell body) NFT remain in the extracellular 
space. The accumulation of these insoluble and proteolysis-resistant NFT can cause the 
disruption of cytoplasmic functions relying on the normal structure of the cytoskeleton, 
and it eventually leads to cell death (Vickers et al, 2000). The neurons of corticocortical 
and hippocampal projections, being highly vulnerable to NFT formation, are damaged 
in AD. The loss of these systems leads to the disconnection between hippocampus and 
neocortex, and between neocortical association areas, resulting in the disintegration of 
intellectual functions (Hof et al.’ 1990). The number of neurofibrillary tangles in the 
neocortex is tightly linked to the degree of dementia (Brion, 1998). 
- 3 -
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1.3 Tail protein pathology and AD 
NFT consists of highly insoluble paired helical filaments (PHFs) in addition to 15 
nm wide straight filaments (Goedert, 1993). The monomer of the main component PHF 
is hyperphosphorylated microtubule associated protein (MAP) tau (Imahori et al, 
1997). 
Tau protein is a microtubule-associated protein, mainly expressed in neuronal cells 
in human. It appears in six isoforms, with 352-441 amino acids, and molecular weights 
range from 45-65 kDa. They are different from each other by possession of none, one or 
two amino terminal inserts and have three or four domains that appear to be the main 
sites for interaction (Buee et al” 2000). It has the function of stabilizing and organizing 
axonal microtubules, which involves in intraneuronal transport (Cross et al, 1993; 
Maccioni and Cambiazo, 1995). It associates microtubule and cytoskeletal elements 
such as actin and plasma membrane to provide mechanical support to microtubule. Tau 
has two domains: The microtubule-binding domain binds to microtubule through 
repetitive regions in the C-terminal part. The repetitive regions are made of three (3R) 
or four (4R) copies of highly conserved 18-amino acid repeats separated from each 






1989). The function of this region is to bind to microtubules. It stabilizes the 
I 
I 
！ microtubule and increases the rate of microtubule polymerization, and to inhibit the rate 
i 
1 of depolymerization (Drechsel et al.，1992). Another domain is the projection domain. It 
I 
I projects from the microtubule surface where it interacts with other cytoskeletal elements 
and plasma membrane. Through this interaction, tau proteins may allow microtubules to 
interconnect with other cytoskeletal components such as neurofilaments and plasma 
membrane. This may restrict the flexibility of the microtubules and produces 
mechanical support to the microtubule in order to prevent it to collapse, thus prevents 
the damage of neuronal cell (Matus et. al., 1994). Tau is necessary for the outgrowth of 
neuritis: Axons show a gradient of tau concentration, with a maximum near the tip 
(Black etai, 1996). 
Tau is a phosphoprotein. Phosphorylation of tau can change its affinity to 
microtubules (Buee et al, 2000). In AD, hyperphosphorylation of tau into PHF-tau 
would cause it to lose its normal physiological function of binding microtubule. Without 
i 
stabilization of tau, microtubule network would be degenerated and these would be 
deleterious to the normal interactions and functions of the cytoskeleton, including 
axonal transport down the axon, maintenance of dendritic and axonal morphology, and 
the regulation of the intracellular localization of other organelles (Mandelkow et al., 
- 5 -
1993). PHF-tau is disintegrated from microtubules and polymerized with straight 
filament to form PHF. Hyperphosphorylation of tau has been proven to be an early 
event in the NFT pathology. Therefore, blockade of this hyperphosphorylation step may 
be a prime target to interrupt the pathogenic cascade (Imahori et al, 1997). 
There are several kinases that can phosphorylate tau. They are proline-directed 
protein kinases, which include mitogen activated protein kinase (MAPK), GSK-Sp, 
tau-tubulin kinase, cyclin-dependent kinases (cdk) 2 and 5，and protein kinase A (PKA) 
(Buee et al, 2000). By immunostaining, only GSK3p and cdk5 are co-localized with 
hyperphosphorylated tau in NFT (Yamaguchi et al, 1996). 
1.4 Tau protein kinase I (TPKI)-- GSK-3P 
GSK-3P has been found as TPKI (Ishiguro et al, 1993). It is an enzyme for 
inhibiting Glycogen Synthase (GS). Two isoforms a and p with molecular weights of 51 
kDa and 47 kDa respectively are encoded by two distinct genes (Woodgett, 1990). In 
human the p isoform is predominantly expressed in the brain compared to the other 
isoforms (Lau et al, 1999). 
GSK-3 is a multi-functional enzyme involved in a broad range of biological 
- 6 -
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processes, including early embryo development, energy metabolism, apoptosis, 
oncogenesis and neurodegenerative disease. Since this enzyme is involved in many 
cellular functions, a tight control in activity is necessary. The inhibitory mechanism is 
predominant because GSK-3 is a constitutively active kinase. The activity of GSK-3 is 
controlled by different signaling pathways via its upstream protein kinases, through 
phosphorylation of the inhibitory site at Ser9. Extracellular stimuli that cause 
phosphorylation-inhibition of GSK-3 include insulin, epidermal growth factor (EGF), 
fibroblast growth factor (FGF) and fVnt ligands (Eldar-Finkelman H，2002). As GSK-3 
is a key regulator of many pathways, elevation in activity would result in many human 
diseases. For example, Wnt signaling is observed in several forms of cancer; chronic 
inhibition of muscle glycogen synthase by elevated activity of GSK-3 would cause 
non-insulin-dependent diabetes mellitus (NIDDM); and elevated activity of GSK-3p 
would cause hyperphosphorylation of tau protein in AD (Doble and Woodgett, 2003). 
GSK-3p was shown to phosphorylate tau at various sites in vitro (Imahori et al., 
1998) and in GSK-3p transgenic mice models into an AD-like form (Lucas et al, 2001). 
In cellular environment, co-expressing GSK-3 (3 with tau would cause tau to lose the 
properties of microtubule binding and stabilization (Lovestone et al, 1996). Transgenic 
mice overexpressing GSK-3 p in brain causes tau to become hyperphosphorylated in the 
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hippocampal region, and neurons exhibit abnormal morphology (Lucas et, al.’ 2001). 
Using double immunostaining, it was found that in AD patient's brain, phosphorylated 
tau (at site Ser413 which is a site specifically phosphorylated by GSK-3 p) and elevated 
level of active GSK-3 p are co-localized with NFT in vivo (Shiurba et al., 1996). 
Moreover, it was found that only the active form of GSK-3 p is present in the NFT (Pei 
et al.’ 1999). GSK-3(3 also contributes to the depletion of acetylcholine in AD. GSK-3p 
is found to interact with pyruvate dehydrogenase (PDH), which is a key enzyme in the 
glycolytic pathway. PDH was phosphorylated in vitro by GSK-3 P to reduce the activity 
converting pyruvate into acetyl-CoA, which is required for acetylcholine synthesis. At 
the same time, the inactivation of PDH would also result in accumulation of pyruvate or 
lactate, energy failure induced by the disturbance of glucose metabolism, and together 
with a shortage of acetylcholine owing to deficiency of acetyl-CoA. They are all 
characteristics of AD brain. Thus GSK-3 p has been proposed to play a key role in the 
pathogenesis of AD. (Imahori et al., 1997) 
1.5 Tau protein kinase II (TPKII)- Cyclin dependent kinase 5 (Cdk5) 
Cdk5 is identified as TPKII. It is a multi-flinction kinase that is implicated in both 
the development and disease of the mammalian central nervous system. Monomeric 
cdk5 shows no enzymatic activity. Its activity is regulated by binding to the activator, a 
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regulatory subunit called p35. Cdk5/p35 does not cause the hyperphosphorylation of tau. 
But when the brain is under neurotoxic insults such as ischemia, oxidative stress and 
Ap42 induced cytotoxicity, p35 will undergo calpain cleavage into a pathological p25 
subunit. The deregulated p25/Cdk5 kinase is neurotoxic and phosphorylates tau in vivo 
on the epitopes affected in AD brains. It is aberrantly up-regulated in AD brains and is 
present in neurons bearing neurofibrillary tangles (Tsai et al, 2004). Moreover, 
deregulation of Cdk5 can be induced by Ap. These features of Cdk5 render it a plausible 
candidate for triggering pathogenic events of AD and linking the plaque and tangle 
pathology. The prospect of deregulated Cdk5 may also contribute to APP processing, 
suggesting a possible positive feedback loop in the pathogenesis of AD (Cruz and Tsai, 
2004). From the above evidence, Cdk5 inhibitor seems to be a promising target for 
therapeutic intervention for AD. However, in vivo inhibition of Cdk5 causes indirect 
activation of GSK-3p (Morfini et al, 2004), which would in turn increase tau 
hyperphosphorylation. Therefore, the drug discovery approach is now focused on the 
specific inhibition of cdk5 activation that is caused by p25 generation and accumulation. 
1.6 Available treatment 
There is no cure for AD. Researchers are still finding drugs that can stop the 
progressive loss of brain cells. However, up to this moment, the only available drug 
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treatments of AD is aimed at slowing down or stabilizing memory loss symptoms, 
together with care strategies and activities that minimize or prevent behavioral 
problems. 
Two classes of drugs are currently approved by The U.S. Food and Drug 
Administration (FDA) to treat cognitive symptoms of AD. The first anti-AD 
medications are acetylcholinesterase inhibitors (AChEI). All of these drugs are designed 
to prevent the excessive breakdown of acetylcholine (ACh)，a chemical messenger in 
the brain that is important for memory and other thinking skills. The drugs work to keep 
levels of the chemical messenger high，even while the cells that produce the messenger 
continue to become damaged or die. It was subsequently demonstrated that treatment 
i ! t 
1 
aiming at, thereby restoring acetylcholine level in AD patients. Three commonly 
I 
prescribed drugs are donepezil (Aricept®)，approved in 1996; rivastigmine (Exelon®)， 
i 
approved in 2000; and galantamine (Reminyl®)，approved in 2001. (www.alz.org ,2004) 
The second type of AD medications can be classified as N-methyl-D-aspartate , 
I 
(NMDA) receptor antagonists. Glutamate plays an essential role in learning and 
memory mediated by NMDA receptors. It is generally accepted that in AD, the activity 
i 
of glutamate receptor-mediated responses are not regulated properly, resulting in the 
causing some AD-like signs and symptoms. The NMDA antagonist memantine 
(Namenda®) has recently been approved by the FDA for treating moderate to severe 
- 1 0 -
AD (Parsons et al,, 1999). 
Vitamin E supplements are prescribed as supplementary treatment for AD, because 
they may help brain cells defending themselves from attack of free radical damage 
(oxidative stress)(Smith et al, 1991). Cells have natural defenses against this damage, 
including the antioxidants vitamins C and E，but with age some of these natural 
defenses decline. Research has shown that taking vitamin E supplements may offer 
some benefit to people with AD. 
All available treatments of AD described above are symptomatic. They only 
targeted to improve the symptoms associated with AD. Different groups of scientists are 
working on the disease-modifying and curative therapy of AD. They are aiming at 
prevention of clinical symptoms: by reducing the formation of NFT and plaques. It is 
found that fibrillar AP aggregates are toxic to neuron cultures and can induce the 
activity of GSK-3p (Cedazo-Minguez et al, 2003), Ap fibril formation seems to be an 
upstream event before tau phosphorylation and neuronal death. A large group of 
scientists are working on preventing the formation of Ap or Ap fibrils. A vaccine 
！ 
AN-1972，designed to prevent plaque formation in the brain, has failed in clinical trial 
as it induces meningoencephalitis in human (Broytman and Malter, 2004). | 
i 
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1.7 Objectives of the present study 
In this study, I focused on the search for novel chemical constituents from natural 
sources for the treatment of AD. The Chinese medicine is a valuable resource for drug 
discovery. Based on the prior knowledge on AD research, AD markers were chosen for 
herbal screening: the inhibitors against glycogen synthase kinase-3 beta (GSK-3P) and 
acetylcholinesterase (AChE). The ultimate goal is to find active components that are 
effective in treating AD by inhibiting these two enzymes. 




Chapter 2 Screening for GSK-3P inhibitors from Traditional Chinese 
Medicine (TCM) 
2.1 Introduction 
2.1.1 Phosphorylation of tau in AD 
In Alzheimer's disease (AD), tau hyper-phosphorylation has been implicated in the 
I 
cellular pathogenesis events. The NFT composed mainly of hyper-phosphorylated tau 
assembled paired-helical filament (PHF), is a major pathological lesion in AD (Goedert, 
I 
1993). Accumulation of hyper-phosphorylated tau is observed prior to neuronal death 
(Kim et al., 1999). As GSK-3p has played an important role in the phosphorylation of 
tau in AD (Cho et al, 2003), it is regarded as a therapeutic target of AD. 
Tau is a phosphorylation primed substrate of GSK-3. Pre-phosphorylation by other 
tau kinases including PKA and CDK-5 facilitates and enhances GSK-3 p mediated 
phosphorylation on other serine/threonine phosphorylation sites (Zheng-Fischhofer et 
al.，1998; Sengupta et al., 1997). Primed substrates that already have a "priming 
phosphate" bind to the specific pocket, aligning them in such a way that GSK-3 can 
phosphorylate a serine or threonine located at the fourth residue upstream to the priming 
phosphate. When this priming phosphate site (Ser9 for GSK-3a/ Ser21 for GSK-3P) is 
pre-phosphorylated by the upstream kinases of GSK3, the binding of GSK-3 towards 
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primed substrate is inhibited (Cohen and Frame, 2001). Inhibitors of GSK-3 that cause 
phosphorylation of Ser9/Ser21, thus blocking the priming phosphorylation site or 
blocking the active site of GSK-3 can inhibit GSK-3 activity towards tau. 
2.1.2 Gsk-3P inhibitors 
The first GSK-3 inhibitor discovered is lithium. It competes with magnesium and 
binds to the magnesium binding site of GSK-3. Lithium has been widely used in 
studying the physiological role of GSK-3. In vitro study demonstrated that lithium 
treatment can reduce tau phosphorylation without changing cell morphology (Lovestone 
et al., 1999)，can prevent neuronal death induced by Ap (Alvarez et al, 1999), and 
inhibit Ap secretion in C0S7 cells transfected with APP (Sun et al, 2002). These 
findings suggested that GSK-3 p might function as a possible mediator for regulating 
both amyloid deposition and tau pathology in AD. Inorganic elements such as beryllium 
and zinc also show inhibition on GSK-3 (Alonso et al, 2004). 
Another major group of GSK-3 inhibitors is small molecules: 
Arylpyrazolopyridazines, pyrazoloquinoxaline and benzazepinones show cross 
reactivity with CDK2. Paullone and indirubins are ATP competitive kinase inhibitors. 
Hymenialdisine is also a ATP-competitive inhibitor of GSK-3, CDK family and 
MAP-kinase inhibitor isolated from marine sponge constituent (Meijer et al” 2000). 
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Derivatives of these compounds have improved potency and selectivity. For 
example, an amine derivative of arylpyrazolopyridazines increases selectivity on 
GSK-3P. Aminothiadiazole derivatives like NNC57-5401 and VX-608; the chemically 
modified indirubins 5,5' -dibromoindirubin and maleimide derivative 
SB-216763/SB-415286 showed great improved selectivity on GSK-3 p. Recently, two 
non-ATP competitive GSK-3 P inhibitors were discovered : thiadiazolidinones (TDZD) 
and halomethylarylketones (HMK). They inhibit GSK-3 without cross-react with other 
kinases. (Alonso et al, 2004) 
GSK-3p is involved in many pathological pathways. Not only AD, inhibitors of 
GSK-3p has been a drug discovery target of these diseases (Fig 2.1). 
• Insulin sensitization 
-Olucose uptake 
• Glycogensynthesis 
A 猶 ocf 丨础(malaria) 
-Bipolar disorder ^ ^ 厂 
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� " � -Maintenance of Epmripotency 
• f'ffP disorders . f^ differentiation -Jet lag 
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Fig 2.1 Pharmacological application of GSK-3 inhibitors (Meijer et al, 2004) 
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Since GSK-3P is a multifunction enzyme with a wide variety of substrate 
specificity, inhibitors with different degree of inhibition and inhibition mechanisms are 
needed. Natural product has been a source of drug discovery. Notable examples are 
recent discovery that natural compounds hymenialdisine and indirubins are potent 
GSK-3 inihbitors. Hymenialdisine is a sponge metabolite, and indimbin is isolated from 
the root of Strobilanthes cusia which belongs to the family Acanthaceae. In Traditional 
Chinese Medicine (TCM)，the use of herbal extracts on treating memory depletion in 
elderly has been applied for many hundred years. In this study, I have made use of these 
Traditional Medicine formulae to screen for novel GSK-3p inhibitors. 
2.1.3 Screening of GSK-3P inhibitor from TCM 
Fifty-five TCM were chosen because of their high occurrence frequency in formula 
for treating memory depletion in elderly (source of medicinal formulae:月窗病良方 1500 
首) .Both aqueous and absolute ethanol extracts were prepared for the initial step of 
screening. A cell model that mimics GSK-3 p-induced tau phosphorylation was used for 
the screening of GSK-3 p inhibitor. After determination of maximum treatment dose by 
MTT cell proliferation test, TCM extract treatment on the cell model was performed and 
followed by western blot analysis of cellular protein. In the first phase of screening, 
only phospho-tau antibody ATI80 was used on the detection of degree of tau 
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phosphorylation in the samples. Three TCMs were found to reduce tau phosphorylation 
I 
I 
and two were found to increase tau phosphorylation in the cell model. The ethanol 
extract of TCM Alpinia Oxyphylla Fructus (AOF)，occurring at approximately 31% of 
I 
I 
the common formulae for treating memory problem, was chosen for further 
I 
I 
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2.2 Material and Methods 
2.2.1 Preparation of extracts and fractions (AOFl-5) 
In the first stage of screening, only aqueous (AOFl) and ethanol (A0F2) extracts 
were prepared from the crude TCM. For identifying active component, the A0F2 
fraction was re-dissolved and divided into aqueous and chloroform soluble fraction. The 





(aqueous extract) (ethanol extract! 
• y 
A0F3 A0F4 
(aqueous soluble (chioroform soluble 
fraction] frsction) 
2.2.1.1 Preparation of aqueous extract of AOF (AOFl) 
The dried herbs (Fig 2.2) were bought from ‘‘北京同仁堂” and they were cut 
into small pieces and blendered into powder. An amount lOg of powder was boiled 
in reflux in 50 ml distilled water for 1 hour. The residue material was discarded and 
the boiled extract was filtered through a 02-\im filter. The filtrate was then 
lyophilized. 
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Fig 2.2 The AOF, literally the bitter Cardamon, or Yi Zhi Ren (益智仁）in 
Chinese，belongs to the family Zingiberaceae. This seed appears in ellipsoidal 
shape with both ends slightly acute 1-2 cm long, 0.7-1.2 cm in diameter. Externally 
brown or grayish-brown, with 13-20 longitudinal, uneven and prominent lines on 
the surface, remains of perianth on the apex and fruit stalk at the base. Thin 
pericarp adhering closely to seeds. Seeds gathered in groups and divided to three 
valves by septum with 6-11 seeds in each valve. Individual seed irregularly oblate, 
with slightly obtuse ribs, about 3 mm in diameter, externally greyish-brown or 
grayish-yellow, covered with pale brown membranous aril. Texture, hard, 
endosperm white. Odour, characteristically aromatic; taste, pungent and slightly 
bitter.(中華人民共和國藥典，1995). 
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2.2.1.2 Preparation of ethanol extracts of AOF (AOF2) 
lOg of AOF powder was mixed with 50 ml ethanol at 4°C for 16 hours and the 
ethanol extract was filtered through a 0.2-|j,m filter. The filtrate was dried in an 
evaporator immersed in a 60°C water bath. The dried material was collected. 
2.2.1.3 Preparation of aqueous fraction of ethanol extract of AOF (AOF3) 
To 2 g of A0F2 in a glass test tube, 4 ml chloroform was added. The solution 
was vortexed vigorously for 1 minute and then 4 ml distilled water was added. The 
mixture was vortexed again for another 1 minute, stand at room temp for 1 hour 
until the aqueous and chloroform layers are separated. The lower aqueous layer 
was collected. The fraction was dried by lyophilization instead of Speedy-Vac dry. 
2.2.1.4 Preparation of chloroform fraction of ethanol extracts of AOF (AOF4) 
The extraction procedure was the same as 2.2.1.3, except that the upper 
chloroform layer was collected and dried under Speedy-Vac at room temperature. 
2.2.1.5 Preparation of essential oil of AOF (AOF5) 
lOg of AOF powder was boiled under reflux in 50 ml distilled water. The 
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steam produced was collected by a condenser and dropped into a reservoir. The 
essential oil was partitioned on the top layer of solution collected from the 
reservoir. This oily layer that contained the essential oils was collected in a 1.5 
microfuge tube. For 1 ml of essential oil, 20 mg of anhydrous sodium carbonate 
was added and incubated overnight to absorb the remaining water. 
2.2.2 General cell culture techniques 
All the cell culture work was performed in an aseptic culture hood and the 
working space was kept sterile by cleaning with 70% ethanol. Other equipment 
including CO2 incubator, water bath and centrifuge were maintained clean by routine a 
check schedule. Consumable materials include culture tubes, culture pipettes, syringe 
and culture flasks were brought sterile and disposed after use. Reagents and buffers such 
as PBS, cultured medium, water, drugs and DNA were prepared using standard sterile 
procedure. 
2.2.2.1 Routine maintenance of cell lines 
All the cell lines including SHSY-5Y, CHO-Kl and COS-7 were cultured in 
Dulbecco's modified Eagle's medium with F-12 nutrient mix (DMEM-F12)， 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine 50 U/ml, 
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penicillin and 0.05 mg/ml streptomycin. The cells were cultured at 37°C in an 5 % 
CO2 incubator. The cells were fed with fresh medium every 3-4 days after passage. 
For cell passage, the cells reaching � 8 0 % confluency were rinsed twice with PBS 
and then trypsinized with 0.05% (v/v) trypsin/ EDTA，incubated at 37 for 3 min, 
followed by th addition of flesh medium to stop the trypsin digestion. Aliquots of 
1/5 to 1/20 of the cells were transferred to new flasks containing fresh medium for 
further cultures. The number of passage was recorded. 
2.2.2.2 Preservation of cell lines 
Cell lines were kept as frozen stocks stored in a liquid nitrogen tank ( -196�C). 
For the preparation of frozen stocks, the cells were collected by centrifugation at 
2000 g for 10 min. The cells were resuspended in an appropriate volume of 
freezing medium at room temperature at the concentration of lO^-lO'^  cells/ml. The 
freezing medium was prepared by mixing equal volume of the fresh growth 
medium with 5-10% DMSO. The cell suspension was dispensed as 1-ml aliquots 
in cryoprotection storage tubes and stored in a liquid nitrogen tank. For cell 
recovery, a cryoprotection tube containing cells was rapidly plunged into a warm 
water bath at 37 The tube was agitated until the suspension was thawed 
completely. The content was transferred to a culture flask containing optimal 
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volume of complete growth medium and incubated in a cell culture incubator (37 
5% CO2). After 24 hr of incubation, the cultured medium was replaced with 
fresh medium. 
2.2.3 3-(4,5-dimethyltiazol-2-yl)-2, 5-diphenyl-tetrazolium (MTT) assay ofAOF 
Cells were seeded in 100 of culture medium in a 96-well culture at 1 x 
cells/well and kept in a humidified atmosphere of 5% (v/v) CO2 at 37°C for 18 hours. 
After incubation, the culture medium is aspirated and replaced with 100 \x\ fresh media 
containing various concentration of AOF extract diluted in serum-free medium (SFM) 
containing not more than 1% DMSO. The cells were further incubated at 5% CO2 37°C 
for 4 hours. After drug treatment, the medium was replaced with 50 i^l of MTT solution 
(15mg/ml dissolved in PBS) (Sigma) and the cells were incubated at 5% CO2 37°C for 2 
hours. After the MTT incubation, 200 [il DMSO was added to each well to dissolve any 
crystals formed. The purple color produced was measured spectrometrically at 
absorbance 540 run with a microplate reader (Bio-Rad，Model 3550). 
2.2.4 Recombinant DNA techniques 
2.2.4.1 Preparation ofDH-5a competent cells 
The strain DH-5a of Escherichia coli (E.coli) was streaked directly from 
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frozen stock onto the surface of a LB agar plate. The plate was incubated for 16 hr 
at 37 °C. A single bacterial colony was picked by a sterile yellow pipette tip and 
inoculated into 10 ml LB medium. The culture was shaken in an orbital shaker at 
37°C for 2 hr, the culture was then further transferred to 100 ml LB medium for 
growth until O.D.600 reached 0.4，which indicated the culture had a cell density of 
4-7X107 cells/ml. Then the culture was chilled in ice for 15 min. The cells were 
collected by centrifugation at 2000 g for 15 min at 4 °C. The supernatant was 
discarded and the pellet was re-suspended in 33 ml of RF 1 solution. The cell 
suspension was chilled in ice for 15 min and then centrifuged at 2000 g for 15 min. 
The resulting cell pellet was re-suspended in 8 ml RF 2 and chilled in ice for 15 
min. The competent cells were then dispensed in 100-|il aliquots to microfuge 
tubes. The tubes were then snap-frozen in liquid nitrogen and stored at -70 °C. 
The transformation efficiency of the competent cells was assessed by transforming 
1 ng of pUC19 plasmid and spread 1/ 10 of the total cells on LB plate containing 
antibiotic ampicillin. The efficiency was calculated by number of colony formed 
when 1 fig of DNA was transformed into the cells. 
2.2.4.2 Transformation of plasmid DNA into DH-5a competent cells 
A frozen tube of DH-5 a competent cells was thawed in ice bath. The plasmid 
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of interest was diluted at concentration 1-10 ng/|il with sterile ddHaO. About 10 ng 
of the plasmid DNA was added to the competent cells and then mixed moderately. 
After incubation of the mixture on ice for 30 min, the DNA-competent cells tube 
was heat-shocked at 42 °C by incubating the tube in a water bath or heat block for 
2 min. The tube was again chilled in ice rapidly for 2 min, followed by the 
addition of 400 i^l of 37°C pre-warmed LB medium to the tube. The tube was 
incubated at 37°C for 1 hour and appropriate aliquots of the cells were spread 
evenly onto LB plates with antibiotic according to the resistance conferred by the 
transformed plasmid. The plate was placed in an inverted position in a 37°C 
incubator for 16 hours to obtain plasmid-containing colonies. 
2.2.4.3 DNA preparation by QIAGEN Plasmid Maxipreps kit (Qiagen) 
A single bacterial colony containing the plasmid of interest was inoculated 
into 150 ml LB medium containing appropriate antibiotic. The medium was 
shaken in an orbital shaker and incubated at 37°C for 16 hr. Then the cells were 
pelleted by centrifugation at 6000xg for 15 min at 4°C. The cell pellet was 
re-suspended in 10 ml of Buffer PI supplemented with 100 \xg/m\ Rnase. 10 ml of 
Buffer P2 was added and mixed gently to the suspension and incubated for 5 min 
at room temperature, followed by the addition of 10 ml Buffer P3 and incubated 
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on ice for 15 min. The precipitation in the mixture was spun down by 20,000 g for 
30 min at 4 During the 30 min, a QIAGEN-Tip 500 was added with 10 ml 
QBT buffer and drained by gravity flow. After the precipitation was spun down, 
the cleared supernatant was transferred to the equilibrated column and emptied by 
gravity flow. Then 30 ml of QC buffer was added to the column for washing and 
the step was repeated again after it was emptied. The plasmid DNA adsorbed in 
the matrix was then eluted by adding 15 ml of QF buffer. An amount of 10.5ml 
(0.7 volume to the eluate) of isopropanol was added to the eluate to precipitate the 
DNA. The mixture was centrifuged at 15,000 g for 30 min at 4 °C. Then the DNA 
was washed with 75% ethanol at room temperature and was recovered by 
centrifugation at 15,000 g for 10 min. The plasmid DNA was then air dried and 
dissolved in desired amount of TE or water. 
2.2.4.4 Phenol/ chloroform extraction of DNA 
The DNA dissolved in water or TE was mixed with equal volume of phenol/ 
chloroform/ isopropanol mixture (25: 24: 1 v/v). The mixture was then mixed 
vigorously by vortex at room temperature for 10 min. The mixture was centrifuged 
at 12,000 g for 10 min, the aqueous phase containing the DNA was transferred to a 
fresh tube. The solution was supplemented with 0.5 mM NaCl and 2 volumes of 
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cold absolute ethanol. The tube was incubated at -70 °C for 30 min. Then DNA 
was pelleted by centrifugation at 12,000 g for 10 min. The pellet was washed by 
75% ethanol at room temperature and redissolved in water or TE in the desired 
volume. 
2.2.4.5 Quantitation of DNA amount and purity by spectrophotometric 
method 
The calculation of DNA concentration by spectrophotometric method is based 
on the following relationship. O.D.260 nm = 1 corresponds to about 50 |ig/ml 
double-stranded DNA or 40 |ig/ml single-stranded DNA or 20 |xg/ml 
single-stranded oligonucleotides. Small amount (1-10 |li1) of DNA sample was 
diluted in 200-1000 |li1 nuclease-free water. The diluted DNA sample was 
transferred to a quartz cuvette and the absorbance at 260 nm was measured in a 
spectrophotometer using water as blank. The reading should be adjusted in the 
range 0.1-1 by appropriate dilution of DNA samples. For checking the purity of 
DNA sample, the ratio of absorbance readings at O.D. 260 nm and O.D. 280 nm 
should be larger than 1.8. 
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2.2.5 Transfection of GSK-3P and tau cDNA into COS7 cells 
C0S7 cells were plated at sub-confluent density in a 12-well plate before 
transfection. For DNA transfection, 2 |j.l of FuGene ™ 6 reagent was added and mixed 
with 0.6 |j.g DNA per well. For transfection per 24-mm well, 2 )li1 of transfection reagent 
was diluted in 65 ofDMEM SFM and incubated for 5 min. 0.3|^g of pCIneo-GSK-3p 
and 0.5 |ag of pCIneo-TauON3R were added in a new microfuge tube. After 5 min, the 
diluted transfection reagent was added drop-wise into the tube containing DNA without 
touching the tube wall and the mixture was incubated for 30 min. A total of 60 [i\ per 
well of the mixture was added evenly to the cells and the plate was returned to the CO2 
incubator at 37°C and incubated for 16 hours. The cells were replaced with fresh media 
with different concentration of drugs diluted in SFM. The cells were harvested after 4 
hours incubation with the drugs. 
2.2.6 Extraction of total proteins from culture cells 
The methods of protein extraction from cultured cells vary according to the 
application. For SDS-PAGE, cells were directly lysed in 2X SDS sample loading buffer. 
For samples required to measure enzyme activity, cells were lysed in the lysis media 
after rinsing the cells twice with PBS. When the cells were grown to about 80% 
confluence in a 12-well plate, 150 \x\ of the lysis medium was added in order to attain 
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the protein concentration of around 1 to 3 |Lig/|il. For SDS-PAGE, cell extract was 
transferred to Eppendorf tube and boiled with sample loading buffer for 10 min. For 
native PAGE, the extract with sample lysis buffer was centrifuged at 12,000 g for 10 
min at 4 °C. The supernatant was transferring to Eppendorf tube and ready for use or 
stored at -70°C. 
2.2.7 Quantitation of protein by the Bradford method 
The protein concentration was routinely measured by the Bradford method. Briefly, 
protein standards (2，4，6，8 and 10 ^ig/ml BSA) together with unknown samples were 
diluted to 0.8 ml water, followed by the addition of 0.2 ml Bradford reagent (Bio-Rad). 
The tubes were mixed immediately until blue color began to develop within 5 min. The 
absorbance at O.D. 595nm was measured by a spectrophotometer. 
2.2.8 Protein separation by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Proteins were separated by SDS-PAGE on a Mini-Protean II electrophoresis cell 
(Bio-Rad). The gel casting unit is composed of 1 long-glass plate, 1 short glass-plate, 2 
spacers and was set up according to the manufacturer's instruction. Water was filled to 
the gel-mould formed by the 2 glass-plates to check for any leaking. The resolving-gel 
- 2 9 -
solution was then mixed according to the recipe (refer to appendix). The percentage of 
polyacrylamide in the mixture could be varied according to desired MW range of 
proteins being separated. A 10% gel was generally used. The volume of the 
resolving-gel mix needed per gel was about 3.2 ml if 0.75 mm thickness gel was made. 
After the resolving-gel mix was pipetted to the gel gap at one side, a thin layer 
(approximately 1 cm) of isopropanol was added. While waiting for the hardening of 
resolving-gel, stacking-gel mix without TEMED was also prepared according to the 
recipe (Table lb). After the resolving layer was formed, isopropanol was removed from 
the gel top. The stacking-gel mixture was added with TEMED and pipetted on top of the 
resolving gel. Finally, the comb for sample slots was inserted into the stacking-gel layer 
immediately. The gel was ready to use after 30 min. 
The gel setup was put in the gel-tank. Fresh SDS-PAGE running buffer was poured 
to the cavity formed by electrode-unit and to the surrounding space. Protein samples 
were mixed with SDS sample loading buffer and boiled for 10 min. Five to twenty 
microlitres of each sample was loaded into the sample slots. The gel was run at a 
constant voltage of 150 V for 50 min or until the tracking dye reaching at the end of the 
gel. 
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2.2.9 Western blot analysis 
After SDS-PAGE，the stacking gel was discarded and the resolving gel was 
equilibrated in transfer buffer for 15 minutes or more. PVDF nitrocellulose membrane 
(Millipore) and 6 pieces of Whatman 3-mm filter paper were cut to slightly large size 
than the gel. For PVDF membrane, it was presoaked in methanol for activation and then 
3 mintues in transfer buffer for equilibration. The 3mm filter paper were stacked into 
two stacks of 3 pieces and wetted with transfer buffer. 
Electroblotting was carried out using a semi-dry electroblotter Trans-Blot Cell 
(BioRad). The gel was placed on top of the membrane was put between 2 stacks of 
prepared filter papers each composed of 3 pieces. The semi-dry blotting was operated at 
a constant voltage of 10 V for 1 hour. Then the membrane was removed and kept wet in 
TBST solution. To block the non-specific binding of antibodies to the membrane, it was 
immersed in blocking solution (5% non-fat milk in TBST) and shaken for 1 hour at 
room temperature. Antibody of appropriated dilution was applied to the membrane and 
incubated at 4 °C for 16 hours with constant shaking. The membrane was then washed 
in TBST solution for 3 times each for 15 minutes. Appropriate secondary antibody 
conjugated with horseradish peroxidase (HRP) was diluted in TBST in a concentration 
suggested by manufacturer with the membrane at room temperature for 1 hour, followed 
by washing in TBST solution 3 times each for 15 minutes. ECL (enhanced 
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chemiluminescence) detection kit (Amersham) was used to obtain signal from the 
membrane. The membrane was exposed to Fuji Medical X-ray Film (Fuji). 
Anitbodies used in this study were: Total tau antibody (DAKO); antibodies ATI80, 
ATS and PHFl recognizing phospho-tau site T231, S202 and S396 respectively (Pierce); 
Total GSK-3p antibody (Signal Transduction); antibody recognizing phospho-GSK-3p 
at site S9 (Santa Cruz Biotechnology); and antibody for actin (Santa Cruz 
Biotechnology). 
2.2.10 GSK-3P kinase assay 
The TCM treated or control cells were washed with PBS for three times and 
then 400 |il fresh lysis buffer was added to the cells. After constant shaking at 4 °C for 
15 min, the lysates were centrifuged at 12,000 g for 10 min and the supematants were 
collected. An amount 50 |il slurry protein A-sepharose bead (Sigma) was added to the 
each lysate. After incubation in a rotator at 4 for 1 hr, the lysate was spun at 6,000 
g for 1 min and the supernatant was collected. An aliquot of 200 fig of total protein from 
each sample was collected for immimoprecipitation and the remaining lysate was kept 
later for Western blot analysis. 
For immimoprecipitation, 0.5 \xg of GSK-3p monoclonal antibody 
(Transduction Laboratories) was added to 200 [ig total protein extract and the mixture 
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was incubated in a shaker or rotator at 4 for 2 hr. The immunoreactive GSK-3P was 
precipitated by adding 50 |il of 50 % slurry protein A-sepharose beads to the mixture, 
incubated further for 1 hr at 4 °C，and spun at 6，000xg for 1 min. The supernatant was 
carefully aspirated without disturbing the bead pellet. The pellet was washed with 400^1 
fresh lysis buffer by inverting the tube four times followed by centrifugation. The 
washing step was repeated twice with wash buffer I and wash buffer II. For the 
preparation of kinase reaction mixture, the kinase reaction buffer was freshly prepared, 
supplemented sequentially with 20 \xM cold adenosine 5'triphosphate (ATP) (Sigma), 8 
HM GS-2 peptide (with sequence YRRAAVPPSPSLSRHSSPHQSEDEEE, 
phosphorylated at Ser-21 by GSK-SP, Upstate Biotechnology) and 7 |LiCi y^^P-dATP 
(Amersham Pharmacia). For control, the lysate was incubated with false GS-2 peptide 
in which the residue Ser-21 is replaced with Ala-21. The no-enzyme control was setup 
by incubating lysis buffer with beads without preincubation with protein lysate. Thirty 
microlitres of the kinase assay reaction mixture was added to the beads to initiate kinase 
reaction. After incubation at 30 °C for 20 min, the reaction was stopped by adding 4x 
SDS sample loading buffer. The reaction mixture was boiled for 5 min and resolved by 
SDS-PAGE on a 25 % acrylamide gel. The gel was then put on a filter paper, wrapped 
in a plastic film and dried at 80 °C in a vacuum gel-dryer for 3 hr. The dried gel was 
then exposed to the Fuji™ Medical X-ray Film for 24 hr. The membrane was 
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re-exposed, if necessary, to obtain the optimal linear range of signals. 
2.2.11 Determination of lithium content by atomic adsorption 
spectrophotometry 
Lithium contamination of sample was determined by means of graphite furnace 
atomic adsorption spectrophotometry. Samples for analysis were diluted with 1% 
DMSO in distilled water to concentrations within the linear range of graphite furnace 
lithium measurements. The diluted samples were transferred to microfuge tubes for 
atomic adsorption spectrophotometer (Varian Graphite Furnace GTA 100/Varian Spectra 
880). Lithium chloride (8 M, Sigma) diluted in 1% DMSO was used as calibration. 
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2.3 Results 
2.3.1 Establishment of a co-transfected cell model for GSK-3P induced tau 
hyperphosphorylation 
To test the effect of TCM on GSK-3P inhibition and tau phosphorylation, COS-7 
cells were transiently over-expressed with tau and GSK-3 p and then these cells were 
treated with various concentrations of TCM extracts. The total cell lysates were 
harvested and subjected to Western blot analysis to tau and GSK-3p antibodies. As 
shown in Figure 2.3, control COS-7 cells without DNA transfection did not express 
detectable level of tau. Only a modest level of endogenous GSK-3 p was expressed in 
control cultures. For comparison, cells were treated with 30mM of lithium chloride 
(LiCl) to inhibit GSK-3 p-mediated phosphorylate tau. Lithium treatment did not cause 
any change in the amount of total tau and total GSK-3p, but lithium did cause a 
significant reduction in the amount of immunoreactive phospho-tau proteins. 
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Fig.2.3 Western blot analysis of total cell lysates in COS-7 co-transfected tau and 
GSK-3 p. (a) Left panel: Western blot on total tau indicating a transient expression of tau 
proteins in transfected cells only; right panel, GSK-313 Western blot indicating an 
overexpression of GSK-3 p expression, (b) Inhibitory effect of lithium (30 mM) on Tau 
phosphorylation. LiCl treatment significantly reduced phospho-tau using 
eiptope-specific phospho-anti-tau antibodies (S202, S396 and T231) without any 
significant change in total tau and GSK-3. 
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2.3.2 Preliminary screening results of aqueous and ethanol extracts (AOFl and 
AOF2) 
2.3.2.1 MTT cell proliferation test result 
Fig.2.4 shows the cyototoxicity test of the extract of AOFl and A0F2 on the 
COS-7 cells determined by MTT proliferation assay. A0F2 appears to be quite 
toxic to the cells at concentrations >100 fig/ml. AOFl was less toxic with the cell 
viability >90% at concentration 160 fig/ml comparing with control. 
2.3.2.2 Western blot analysis of cell lysate 
In the preliminary screening, only anti-phospho-tau antibody ATI80 (T231) 
was used. TCM treated sample lysate shows reduction on tau phosphorylation, that 
was, reduction in immunoblot signal on ATI 80 comparing with control will be 
selected for further screening. Fig 2.5 compares the result of aqueous and ethanol 
extract of AOF (AOFl and A0F2). Treatment doses selected according to the MTT 
proliferation test result for AOFl and A0F2 were 160 |ig/ml and 80 }ig/ml 
respectively. Treatment of A0F2 caused reduction in tau phosphorylation. 
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Fig.2.4 The cytotoxicity test of the TCM AOFl and A0F2 on COS-7 cells. Cells were 
treated with various concentration of AOFl or A0F2 for 4 hours and the viability of 
cells were determined by the MTT assay. Data are presented as the percentage of viable 
cells compared to no drug control. All data were expressed as mean 士SD (n=3) 
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Fig.2.5 Effect of the AOFl and A0F2 on GSk-3p mediated tau phosphorylation in 
COS-7 cells. Cells were transiently co-transfected with tau and GSK-3p cDNAs and 
then treated with either DMSO in SFM (control), 30mM LiCl, 160 [ig/ml AOFl, or 
80 [ig/ml A0F2 for 4 hours and then cells lysates were prepared, subjected to Western 
blot analysis using primary antibody ATI 80 (recognize phospho-T231 of tau protein). 
All samples were carried out in duplicates. 
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2.3.3 Ethanol extract of AOF inhibits GSK-3P induced tau phosphorylation in 
COS-7 cells 
After the preliminary screening process, the ethanol extract of AOF (A0F2) was 
chosen for further study. In order to further characterize the effect of A0F2 on tau 
phosphorylation, the cell lysates after treating with A0F2 were probed with different 
antibodies against different eipitopes of phospho-tau. Fig 2.6 shows that COS-7 cells 
treated with 80 |ig/ml ethanol extract of A0F2 caused a significant reduction in 
phospho-tau immunoreactivities using four epitope-specific anit-phospho-tau antibodies. 
All of the antibodies used, T231, S396 and S202 that recognize the 
phospho-serine/threnoine were inhibited by treatment with A0F2. This result confirmed 
that A0F2 specifically inhibited the serine/threonine phosphorylation of tau at sites that 
have previously been shown to be phosphorylated by GSK-3 p. By contrast, there was 
little change in the level of total tau and GSK-3 p. 
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Fig 2.6 Effect of the A0F2 on GSk-3p mediated tau phosphorylation in C0S7 cells. 
Cells were transiently co-transfected with tau and GSK-3p cDNAs and then treated with 
either DMSO in SFM (control), 30mM LiCl or 80 |ig/ml A0F2 were subjected to 
Western blot analysis. All samples were carried out in duplicates. 
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2.3.4 Effect of the sub-fractions of the ethanol extract of AOF on tau 
phosphorylation on COS-7 cells 
As described in the Materials and Methods, the ethanol extract of AOF was back 
extracted with chloroform to obtain the chloroform-soluble and chloroform-insoluble 
fractions, designated as A0F3 and A0F4. Solvent extraction of plant is based on the 
difference in solubility between components. AOF was first extracted with absolute 
ethanol (A0F2), certain types of molecules were dissolved in ethanol: When the dried 
ethanol extract was redissolved in 1:1 chloroform:water, the essential oil, organic 
pigments and organic alkaloids would dissolve in chloroform (that is, fraction A0F4). 
Glycosides, alkaloidal salt, aqueous soluble pigments and tannins are soluble in the 
aqueous fraction (fraction A0F3)(中藥化學實驗與技術，1986). These fractions were 
examined for their effects on GSK-3 p induced tau phosphorylation 
2.3.4.1 MTT proliferation test ofAOF3 and AOF4 
Fig 2.7 shows the cytotoxic assay of the sub-fractions of the ethanol extract of 
AOF: the chloroform-soluble fraction (A0F3) and chloroform-insoluble fraction 
(A0F4) on COS-7 cells. A0F3 has low toxicity towards the cell line as the cell 
viability remains over 80% at concentration 300 i^ ig/ml. A0F4 showed a slight 
increase in toxicity when compared with A0F2. Cell viability of 80 |ag/ml A0F4 
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treated C0S7 was slightly lower than 80%. 
2.3.4.2 Western blot analysis of AOF3 and AOF4 treated cell lysate 
As shown in Fig 2.8, COS-7 cells treated with 80|Lig/ml A0F4 for 16 hrs 
resulted in a significant reduction in phospho-tau S396 immunoreactivity. By 
contrast, the total tau and GSK-3p immimoreactivities remained unchanged. It is 
interesting to note that the pattern of tau-phosphorylation inhibition is different 
from those obtained from lithium treatment. The immunoreactive protein bands 
were shifted downward, indicating a general reduction in the degrees of tau 
phosphorylation. It is generally accepted that a decrease in protein 
phosphorylation leads to an increase in mobility on SDS-PAGE. In contrast, the 
chloroform-insoluble fraction (A0F3) of the back-extract ethanol extract of AOF 
did not have any effect at concentrations as much as 200|ig/ml (Fig 2.8b). 
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Fig 2.7 The cytotoxicity test of the A0F3 and A0F4 on COS-7 cells. Cells were 
treated with various concentrations (a) A0F3 or (b) A0F4 for 16 hours and the viability 
of cells were determined by the MTT assay. Data are presented as the percentage of 
viable cells compared to no drug control. All data were expressed as mean 士SD (n=3) 
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Fig 2.8 Effects of AOF3, A0F4 and lithium on tau phosphorlyation. COS-7 cells 
transiently over-expressed with GSK-3 p and tau were treated with DMSO in SFM 
(control), 30mM LiCl or in 200 |ag/ml A0F3 (a) or in 4P|ig/ml and 80 ^ig/ml A0F4 (b). 
The cells lysates were then analyzed by Western blot analyses on phospho-tau (S396), 
total tau and GSK-3 p. All treatments were done in duplicates 
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2.3.5 Effect of the essential oils of AOF on GSK-3P induced tau 
phosphorylation 
Assay results showed that the active component was presented in the fraction 
A0F4, that is the chloroform-enriched ethanol extract. The search of active component 
could be confined to 3 types of molecules: essential oil, organic pigment and organic 
alkaloid. Since organic pigment is only presented in trace amount, and most types of 
alkaloid are presented as alkaloidal salt and dissolved in aqueous solution, the 
ethanol-chloroform extract is mainly consists of essential oil. 
The essential oil of AOF could be separated through steam distillation. In this study, 
the possibility that AOF may contain active constituents from the essential oils was 
explored. 
2.3.5.1 MTT proliferation test of AOF5 
Fig 2.9 shows the cytotoxicity test on COS-7 cells treated for 16 hrs with the 
essential oils of AOF (A0F5). The essential oil of AOF was quite cytotoxic to 
COS-7 cells with an estimated LD50 between 21 |Lig/ml and 42 ^ig/ml. 
2.3.5.2 Western blot analysis 
Because of the fact that the essential oil is relatively toxic to cells, the 
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concentration of the essential oils of AOF were tested at much lower dosages at 21, 
16 and 10 |j.g/ml. The COS-7 cells were incubated for 16 hrs for transient 
over-expression with tau and GSK-3p and then treated with AOF essential oils for 
4 hrs. After drug treatment, the cells were harvested for Western blot analyses on 
phospho-tau and GSK-3p/S9. As shown in Fig 2.10，the A0F5 caused a 
dose-dependent inhibition of tau phosphorylation at three epitopes (S203, S231, 
S396). The extent of inhibition was similar to those cells treated with 30 mM LiCl. 
The inhibition of tau phosphorylation by A0F5 was more prominent at sites S396 
and S202. The concentration of AOF at 21 |ig/ml produced a similar inhibition 
profile to that by LiCl, suggesting the effect is mediated by GSK-3P inhibition. 
However, Western blot analysis probed with GSK-3P-S9 antibody indicated that 
while LiCl increased the level GSK-3P-S9 phosphorylation, AOF essential oil 
caused a dose-dependent reduction of GSK-3p-S9 phosphorylation. This reduction 
is not likely due to a reduced level of GSK-3p because the total 
GSK-3P immunreactive protein appeared unchanged by AOF treatment. 
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Fig 2.9 The cytotoxicity test of the essential oils of AOF on COS-7 cells. Cells were 
treated with different concentration of the essential oil of AOF for 4 hrs. The viability of 
cells were then examined by the MTT proliferation assay,. All data were done in 
triplicates and presented as mean 土SD (n=3) 
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Fig 2.10 Effect of essential oilof AOF on tau and GSK-3P phosphorylation. COS-7 
cells transiently over-expressed with tau and GSK-3p were treated with DMSO in SFM 
(control), 30mM LiCl, 10 i^g/ml，16 |ag/ml and 21 |ig/ml AOF essential oil for 4 hours. 
The cell lysates were prepared and then subjected to Western blot analyses. The first 
three blots were probed with anti-phospho-tau antibodies (S202, S231 and S396), that 
specifically detect the tau phosphorylation sites known to be phosphorylated by 
GSK-3P of tau. GSK-3p-S9 antibody recognizes the phospho-S9 of GSK-3p and 
GSK-3 P recognizes the total GSK-3 p. An increase in S9 phosphorylation is consistent 
with an inhibition of GSK-3 P activity. 
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2.3.6 The effect ofAOF essential oil on GSK-3p activity in COS7 
Fig 2.11 shows the results of an in-vitro GSK-3p assay on tau/GSK-3p 
over-expressed COS-7 cells after treating with AOF essential oil or with 30 mM lithium. 
As would be expected, the GSK-3P activity was reduced by lithium, particularly at high 
dose (30 mM). Similarly, cells treated with AOF essential oil showed various degrees of 
reduction in GSK-3P activity. No background signal was detected at the 
without-enzyme control, The specificity of GSK-3P activity was confirmed by the lack 
of phosphorylation on a false substrate GS-2 (in which the phospho-S21 of the GS-1 
was replaced by A-32). No Signal was observed in samples with the false substrate. The 
AOF and lithium mediated reduction in GSK-Sp activity was not due to a variation in 
cellular proteins, as indicated by similar amount of p-actin in each sample. 
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Fig 2.11 Effect of the essential oil of AOFon GSK-313 kinase activity in tau and GSK-3 p co-transfected 
cells. Cells were treated for 4 hrs and then harvested for immimoprecipitation and kinase assay. The 
autoradiograph signal was produced by the ^^ P labeled GS-2 peptide resolved in 25 % acrylamide gel. 
GSK-3p activity was estimated by the signal intensity which was proportional to amount of ^^P-labelled 
GS-2 peptide. The cells were treated with solvent control (1%DMS0 in SFM), 20mM LiCl, 30mM LiCl, 
10 ng/ml, 16 ng/ml and 21 ^ig/ml respectively. The graph shows the relative GSK-3 p activity comparing 
with the control. Data of p-actin blot were used to normalize the amount of protein samples used in each 
treatment. The upper right panel shows a control experiment which samples treated with SFM were 
incubated with untreated cell lysate (lane 1), lysis buffer only (lane2) and untreated lysate with false GS-2 
peptide (lane 3). 
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2.3.7 Lithium content of AOF extracts 
Heavy metal contamination of plant might be brought by water pollution. There 
would be a false positive result if the herb is contaminated with lithium, the inhibitor of 
GSK-3. Therefore, the AOF extracts that have an effect on reducing tau phosphorylation 
were subjected to the measurement of lithium content by atomic adsorption 
spectrophotometry using a Varian Spectra Atomic Adsorption spectrophotometer. The 
standard curve was constructed with known concentrations of lithium. The table below 
shows the standard curve of the lithium calibration by atomic adsorption 
spectrophotometry. 
Lithium concentration Absorbance 
(OD670) 
0.944 |iM (40 |ig/L) 0.014 
1.415 ^M (60 i^g/L) 0.026 
2.359 | iM(100 ^ig/L) 0.044 
The fractions that exhibited GSK-3 p inhibitory activities were examined for the 
presence of lithium. Both the A0F2 (200 |ag/ml) and A0F5 (83 |^g/ml) contained 
lithium at concentrations less than 0.9 |iM (absorbance = 0.001)，indicating that very 
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little amount of lithium contamination was present in these extracts. 
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2.4 Discussion 
In this study, mammalian COS-7 cells were transiently transfected with GSK-3p and 
tau to establish an in vitro tau phosphorylation cell model. The effect of lithium chloride 
(LiCl) was also examined for comparison. Previous research has shown that 20mM LiCl 
could effectively inhibit tau phosphorylation mediated by GSK-3p (Kelin and Melton, 
1996). More than 80% of GSK-3p activity was inactivated by 20mM of lithium 
monovalent cations. 
A high dose of AOF could cause severe cell death. Therefore, AOFl was used at a 
dose 160 )ag/ml and A0F2 was used at a dose of 80 |ig/ml that did not cause 
significantly toxic effect to the cells. Preliminary screening showed that the amount of 
phospho-tau was decreased after A0F2 treatment, which was detected by 
phospho-dependent tau antibody ATI80 (recognize phospho-T231-tau). Only ATI80 
was used in preliminary screening because it produced most observable different in 
western blot signal upon the treatment of 20mM LiCl (Fig. 2.2). 
Further analysis was carried out using different antibodies showing that there is no 
indication that AOF treatment changed the level expression of total GSK-3P or total tau 
proteins. As demonstrated by Western blot, the intensity of immunoreactive total tau and 
and total GSK-3p remains unchanged. However, the phosphorylation of tau was 
decreased which could be consistently observed in Western blots probed with various 
- 5 4 -
anti-phospho-tau antibodies (ATI 80, ATS and PHF-1 recognizing T231, S202 and S396 
respectively). It was therefore concluded that the ethanol extract of AOF inhibited 
tau-phosphorylation at sites T231, S202 and S396，presumably by affecting the activity 
of GSK-3p. Among the sites of tau phosphorylation, the S396 and S202 were found to 
be specific to GSK-Sp mediated phosphorylation. GSK-3p predominately 
phosphorylates Ser/Thr-Pro motifs of tau proteins which occur in closely spaced pairs, 
in order Ser396/Ser404, Ser45/Thr50 and S202/T205 followed by others (Godemann et 
al, 1999). This conclusion is further confirmed by a parallel study in which the cells 
were treated with 20 mM LiCl instead. Lithium has previously been demonstrated to 
have potent inhibitory effect on GSK-3p. 
In order to find the active constituents present in AOF contributing to the inhibitory 
effect, the dried ethanol extract of AOF was re-dissolved into 1:1 chloroform:water and 
the resulting ethanol-aqueous and ethanol-chloroform fractions (A0F3 and A0F4) were 
obtained for inhibition assay. This time, the phosphor-dependent tau antibody PHF-1 
(which recognize S396) to monitor the GSK-3p inhibition. Since the phosphorylation 
site S396 is more specific to the activity of GSK-3p. Even though the antibody does not 
produce an observable signal as ATI 80. It was found that the chloroform-soluble 
fraction retained the tau phosphorylation inhibitory activity whereas the 
chloroform-insoluble fraction was inactive, even at very high dosage >200 |ig/ml. The 
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result clearly showed that the active component is/are lipid-soluble. It is however 
interesting to note that the inhibition profile of AOF treatment is slightly different from 
those cells treated with lithium. By comparing the total tau with the control, the 
AOF-treated tau immimoreactivity was detected which migrated slightly faster than 
those from control cultures. The data suggested that the general degree of tau 
phosphorylation was inhibited by 80 |ig/kg A0F4. As we expected that the A0F4 
sub-fraction should have a higher potency than the ethanol extract of AOF, however, the 
effective dose of A0F4 was same to the ethanol extract (80 |Lig/kg). This phenomenon 
could be explained by the lost of active component during sub-fractionation, which 
involved the solvent rehydration and dehydration of the AOF ethanol extract. The 
sub-fractionation of the AOF ethanol extract has failed in concentrating the active 
component, but at least it had proven that the active component is presented in 
chloroform-soluble fraction. 
Based on this finding, the search of active component was confined to the 
chloroform soluble fraction. Since this fraction consists of mainly essential oil, the AOF 
essential oil was separated for further analysis. Essential oil is a complex mixture of 
volatile components of plants, which can be extracted by distillation through hot steam. 
The essential oils have boiling points ranging from 70-350�C and exist as liquids at 
room temperature. The oil is soluble in chloroform, methanol, ethanol, hexane, ether 
- 5 6 -
and petroleum ether and consisting of small organic molecules. The essential oil can be 
classified into two groups: hydrocarbons and oxygenated compounds. The terpenes: 
monoterpenes, sesquiterpenes, and diterpenes are major constituents of hydrocarbons 
while esters, aldehydes, ketones, alcohols, phenols and oxides are common oxygenated 
essential oils.(中草藥成份化學，1977;植物化學，1985). 
The essential oil of AOF was found to have a similar inhibitory effect on tau 
phosphorylation. This inhibition could be explained by an inhibition of tau kinases. 
Analyses of GSK-3P-S9 and total GSK-3P immunoblots suggested that the A0F5 did 
not increase the phosphorylation of GSK-3 p at Ser-9, which is a prime phosphorylation 
site for negative regulation of GSK-3 p activity. Lithium treatment was found to inhibit 
GSK-3p activity by an increase in GSK-3-Ser-9 phosphorylation (Lee et al, 2002), the 
effect of which is confirmed in the present study. 
Treating the cells with A0F5 causes a decrease in GSK-3P-S9 phosphorylation, 
but direct measurement of the in vitro GSK-3 p activity indicated a reduction of enzyme 
activity. The result seems to contradict with each other. One explaination is that there 
might be 2 different components inside AOF essential oil: one would be the enhancer of 
GSK-3 p (causing Ser-9 phosphorylation) and another one would be a GSK-3 p inhibitor, 
Note that Ser-9 phosphorylation inhibits GSK-3 p by preventing the binding of primed 
substrate. If the inhibitor binds to the site Ser-9, it can provide a similar inhibitory effect 
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without Ser-9 phosphorylation detected in immimoblotting. In summary, the present 
study provides preliminary evidence that the essential oil of AOF could inhibit tau 
phosphorylation that might be mediated by a reduction in GSK-3 p activity not through 
Ser-9 phosphorylation. 
In Traditional medicine, AOF improves memory depletion caused by qi deficiency, 
warms spleen and stops diarrhea. AOF served in alcohol has effect on yang tonic, 
warms kidneys and reduces frequent urination (中華人民共和國藥典，1995). In 
Western countries, it was used for treating hypertension and cerebrovascular disorders. 
An aqueous extract of AOF has previously shown to have neuroprotective effect on 
primary cultures against Ap induce toxicity and free radical attack (Koo et. al, 2004). 
Oral administration of this extract also protects mice from ischemic insult. The authors 
suggested that the AOF aqueous extract's neuroprotective effect was contributed by the 
reduction on NO-mediated formation of free radicals (Koo et, al, 2004). Taken these 
data together, it would appear that both the aqueous and ethanol extracts of AOF contain 
active ingredients that help to improve the memory deficit problems in patients. Further 
analysis on the identification of chemical constituents in the ethanol and essential oils is 
necessary in order to characterize the mechanism of drug action on GSK-3 mediated tau 
protein phosphorylation. 
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Chapter 4 Evaluation of the in vivo efficacy of cryptotenshinone (CT) 
in Morris Water Maze Task (WMT) 
4.1 Introduction 
4.1.1 Involvement of Cholinergic system in cognitive dysfunction in AD 
A reduction in synaptic density and loss of neurons in basal forebrain region is 
considered to be responsible for the decline in cognitive dysfunction in AD. The 
decrease in choline acetyltransferase (ChAT) activity (Perry et al, 1981), increase in 
butylcholinesterase activity (Giacobini, 2003), decrease in choline uptake (Rylett et al, 
1986)，increase in ACh efflux (Nilsson et al, 1986)，decrease in both nicotinic and 
muscarinic ACh receptor bindings (Lemiere et al, 1999) are significantly correlated 
with the progression of disease in AD. In the early stage of the disease, loss of 
cholinergic neurons is found in nucleus basalis of Maynert (NBM), which is a small 
group of cholinergic nerve cells in the forebrain that connected to areas of the cerebral 
cortex. The deficit in the above basal forebrain cholinergic system is supported by 
psychopharmacological evidence in which administration of cholinergic receptor 
antagonist, scopolamine, decreased memory task performance in rodent and humanoid 
(Miller and Desimone, 1993; Aigner and Mishkin 1993; Aigner et al, 1993)，a deficit of 
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memory task performance similar to those occur in AD patients (Smith et of/., 1990) 
4.1.2 Animal model for Alzheimer's disease 
In order to facilitate pre-clinical assessment of novel drugs for treating AD, a 
number of animal models have previously been developed. Many of these models 
involve the generation of cognitive deficits in rodents by genetic manipulations or by 
pharmacological means so as to reproduce some typical AD symptoms such as spatial 
memory decline. Transgenic mice model of amyloidogenesis by genetic modifications 
was well developed. Several transgenic lines were produced which express human APP, 
Ap，or APP genes carrying familial AD mutation. These transgenic mice exhibits some 
degree of pathological changes that include amyloid deposit, neuritic plaque formation, 
synaptic loss and astrocytosis, although none of these animals showed obvious neuronal 
loss as consistently observed in AD (Yamada and Nabeshima, 2000). Other models 
include the transgenic rodents with human tau or GSK-Sp in the hope to increase 
tauopathy phenotype (Lucas et al, 2001; Hemandex et al, 2002; Arendt et al, 1995). 
Transgene mice that mimic cholinergic deficit in AD by over-expression of human 
acetylcholinesterase (Berri et al, 1995) or generation of lesions to the NBM (Winker et 
al, 1995) were also produced. Despite extensive use of these models in pharmaceutical 
industries and academic research, there is however no perfect animal models that could 
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mimic all the cognitive and behavioral abnormalities observed in patients with AD. 
The most common animal model based on pharmacological manipulations was 
produced by the administration of anti-cholinergic drug, scopolamine (Beatty et al, 
1986). These scopolamine-treated animals produce deterioration in memory test 
performance, which could be reversed by pre-treatment with AChE inhibitors (Smith et 
al, 1990). This model is commonly used to assess the drug efficacy for improving 
memory deficit. 
4.1.3 Morris Watermaze Task (WMT) 
The memory deficit in rodents could be assessed based on Morris Watermaze Task 
(WMT). Originally developed by R. Morris in 1984，this task is based upon the premise 
that animals have evolved an optimal strategy to explore their environment and escape 
from the water after a minimum amount of training (Morris, 1984). Experimentally, 
mice are released in a pool of water and allowed to be rescued by reaching a hidden 
platform. Their spatial memory and learning can be reflected by their strategy to search 
the platform by memorizing the distant visual cues. The mice that learn and remember 
the spatial cues would find the platform in the shortest time. With the help of computer 
and tracking software, the gain in spatial accuracy of the mice can be measured as 
parameters generated from the captured swimming path. By comparing parameters 
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between different treatment groups, one can access the effect of drug on mice behavior. 
4.1.4 Study of the in vivo efficacy of cryptotanshinone (CT) 
The project was originated from the search of AChEI from TCM in the laboratory. 
Previous work done in our laboratory showed that crytotanshinone (CT), an active 
constituent of a famous TCM Danshen, inhibits AChE activity in an in- vitro assay with 
IC50 at about 5-8 |j.M (Ho, 2003). This result raised the opportunity that the drug could 
be used to treat early stage of AD patients. In order to explore this possibility, the effect 
of CT on scopolamine induced spatial memory impairment was studied in the present 
thesis. 
An in-house water maze system was setup to test CT's in vivo efficacy. Male 
BALB/c mice were chosen as animal subjects. Before testing the effect of CT on 
behavioral performance, toxicity of treatment dose of CT should be tested. To confirm 
whether chronic use of CT would cause toxic effect, mice that were continuously 
administered with CT (10 mg/kg i.p.) for 10 days and then the plasma AST and ALT 
enzyme activities were measured to evaluate if the drug produces any liver damage to 
the animals. In WMT, the male BALB/c mice were first trained to locate the relative 
position of escape platform from the external cue. Training session includes 24 training 
trials on 5 consecutive days. The first two training days made the mice adapted to the 
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WMT, and starting from day 3, mice were divided into 2 groups, which 10 mg/kg CT or 
vehicle would be injected to the mice each day until the end of the experiment. Training 
session was continued until day 5. Mice which met the selection criteria would be 
proceeded to the scopolamine resistance test. In the scopolamine resistance test, 0.5 
mg/kg scopolamine was injected before probe test, which is a test giving parameters of 
spatial accuracy (detail will be explained in next session). Previous research showed 
that 0.5 mg/kg scopolamine successfully produce spatial impairment in rodents (Wang 
et al, 2000; Smith et al, 2000). By comparing probe test result between the CT 
pretreated or control group, the effect of CT on reversing scopolamine insult can be 
studied. 
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4.2 MATERIAL AND METHODS 
4.2.1 Morris Water maze setup 
For the set-up of watermaze, a circular pool (Im diameter and 40cm height) was 
made of polyvinyl chloride (PVC) with black-paint inside. The pool was arbitrarily 
divided into four quadrants SE, SW, NE and NW. A black platform with diameter of 10 
cm was submerged at the center of the target quadrant 1 cm below the surface of the 
water. Four bright colored geometric cards acting as external cues were placed at four 
comers above the pool. A video camera was located at approximately two meters above 
the center of the pool. The swimming activities were recorded and captured on a 
computer equipped with a video tracking system. The video tracking system was kindly 
written by Gary Wong of Automation and Computer-aided Engineering, and modified 
by John Cheng of System Engineering at The Chinese University of Hong Kong. 
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Fig 3.1. (a) The Watermaze setup consists of a circular pool (1-m diameter and 40cm 
height) made of polyvinyl chloride painted in black inside. Highly visible cues are 
located at the side of the pool. A camera was located 2.2m above the center of the pool, 
that was connected to a computer equipped with a video tracking software, (b) The pool 
is conceptually divided into four quadrants (SE, SW, NE and NW). A black platform 
with diameter of 10 cm was submerged at the center of the target quadrant, (c) A typical 
graph showing the tracking of the path of a mouse swimming in the water maze. The 
videos and pictures were compressed in MPEG-4 andjpg formats. 
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4.2.2 Animal model 
Both rats and mice are natural swimmers and they can be used in WMT. Usually 
rat is preferred because of its stability. They show a better performance in acquisition 
and a smaller trial-to-trial variation in training. Mice are more temperamental, they may 
have the option of stopping and floating or not willing to stay on the platform. Although 
mice have such disadvantages, it was chosen as the animal model for this study because 
they were easy to handle, and use lesser drugs, as compared to rats. 
Species of mice was another influential factor. A review compared task 
performance of four strains of mice 129/Ola, BALB/c，C57BL/6 and FVB/N (Royal et 
al, 1999). Good spatial learning was observed in the first three strains of mice and the 
work suggested that FVB/N might not be suitable to the task involving memory and 
learning. BALB/c was available from the Laboratory of Animal Service Centre CUHK, 
therefore it was chosen to be the animal model. 
Male BALB/c mice (8-10 weeks old and weight �20-26 g) were held in the 
Laboratory Animal Services Centre of the Chinese University of Hong Kong. The 
animals were kept in a temperature-controlled room with a 12-hour light/ dark cycle and 
food and water supplied ad labium. Behavioral experiments were conducted during the 
light cycle. 
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4.2.3 Drug preparation 
Cryptotanshinone (CT) was obtained from National Institute for the Control of 
pharmaceutical and Biological Products. It was dissolved in a solution at 1 mg/ml of 5% 
polyethylene glycol, 2% N,N- dimetylacetamide in PBS. Scopolamine (Sigma) was 
dissolved in a concentration of 0.5 mg/ml in PBS. Drug solutions were prepared freshly 
on the day of injection. 
4.2.4 Toxicity test ofCT 
Sixteen BALB/c male adult mice were injected intraperitoneally (i.p.) with 10 
mg/kg CT per day. Another group of mice (n=16) were injected with vehicle only as 
control. After daily injection of 10 mg/kg CT for 10 days, mice were sacrificed and the 
blood samples were collected by cardiac puncture in tubes containing 100)^ 1 
anti-coagulant, heparin (Sigma). Plasma samples were freshly prepared by 
centrifugation of blood samples at 2000 rpm for 10 minutes. The plasma samples were 
used for assays of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
using commercial kits (BioSystem). In each sample group, blood samples of 16 male in 
each group were subdivided into two groups of eight. Eight samples were subjected to 
AST assay and another eight samples were subjected to ALT assay 
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4.2.5 Water maze task (WMT) 
The WMT included a 5-days training session followed by two scopolamine 
resistance tests. The flowchart of the experiment is summarized below. 
Scopolamine resistance test 2 
Scopolamine resistance test 1 
Pre-tiain probe test Posttrain probe test 
Training session 
V — ^ 
Day 
1 2 3 4 5 6 7 
CTA^ehicle treatment 
4.2.5.1 Training session 
Stress can greatly influence task performance. Therefore, several measures 
had been taken to avoid stress: water temperature was kept between 22-27�C to 
avoid stress by cold; the experimental place was an isolated area which was free of 
noise; experiment was carried out at a fixed time everyday so that mice could 
prepare for swim in mind; an infra-red light was used to warm the mice after 
swimming; after injection of CT or vehicle, the mouse would have 20min to 
recover before training; different colors of gloves were used during training and 
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during injection to make them accustomed to the manipulations and handling. 
Mice were given a series of 24 training trials for five consecutive days. The hidden 
platform was fixed in the pool in one quadrant. In every trial, the mouse was 
gently released at one quadrant facing the wall of the pool. The hidden target was 
randomly scheduled, allowing the animal to search for the platform within 90 
seconds. The time reaching the platform (i.e. latency of escape) in each trial was 
recorded. The mouse failed to reach the platform within 90s were considered 
failed to accomplish the task. All mice were allowed to take a rest for 20s after 
reaching the platform. 
Starting from day 3 of training, 24 BALB/c male were divided into two 
groups: the cryptotanshinone-treated (CT) and the control group. Each group of 
the animals received daily injection of CT or vehicle as described in the previous 
section at the third day after the initial swimming section. On each day, the drug 
was administered an hour prior to the training. 
At the beginning of the training, a pre-training probe test was conducted on 
Day 1. In the probe test, mice were allowed to swim freely in the pool for one 
minute without platform. The swimming paths of the mice were captured and 
analyzed by the software. The spatial accuracy was expressed by two parameters: 
the percentage of time spent in target quadrant (%T) and average distance from 
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target (AvgD). In day 5，a post training probe test was conducted after the last 
training trial. 
Probed test in WMT was used to assess the mice's spatial accuracy. Although 
WMT performance could be revealed in escape latency, probe test gave a better 
analysis to the strategy used by the mice to locate the platform. The mice were 
expected to solve the water maze purely by reference to the spatial cues, but there 
were mice using praxis strategy: adapt to and sequence of movement that can 
bring them to the platform . For example, swimming in circular path at a fixed 
distance away from the wall, or by just swimming randomly in the pool until 
reaching the platform by chance. These mice could have a relatively low latency 
of escape in the training session. When the platform was removed in probe test, 
the swimming path of the above mice was dispersed compared to those mice 
which had acquired the position of platform by distal cues and search repeatedly 
around the platform. 
Although probe test gave a more accurate measurement of spatial accuracy, 
escape latency was used instead of probe test to assess the improvement of mice 
during the 5 days training session. The reason was that probe test could not be 
done frequently, since mice would become confused if the platform was removed 
while they were not yet familiar with the task. 
- 7 0 -
4.2.5.2 Scopolamine resistance test 
In day 6, two trials were given to all mice prior to a probe test. Then all mice 
were injected with 0.5 mg/kg scopolamine (i.p.). After 20 minutes, another probe 
test was performed. The AvgD and %T of mice before and after scopolamine 
treatment were compared so as to assess the impairment brought by scopolamine 
insult. 
Probe test depends on the strategy that the mice's initial search for the 
platform. On the other hand, it is pre-assumed that the mouse does not know the 
platform has been removed from the pool. If the mouse realized that the platform 
has been removed after several attempts, it might switch to another survival 
strategy like randomly explore through out the pool to find a platform or trying to 
find an exit along the wall. To compensate the disadvantage of probe test, another 
test was applied in parallel to assess the effect of the drugs. Unlike probe test, 
platform was present in this test. The mice would carry out training session before 
and after scopolamine injection. 
This test was performed in day 7. In day 7，after injection of CT and vehicle, 
two swimming trials were given to mice prior to the injection of 0.5 mg/kg 
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scopolamine. A training session was carried out after scopolamine injection. The 
swimming path of the mice at the second trial and the third trial, which was 
carried out 20 min after scopolamine injection, were captured. Two parameters 
were adopted to assess performance: the escape latency and the search efficiency 
index (SEI). Usually, during training session, the escape latency was used as 
measuring parameters. If a capturing system is available, cumulative distance from 
start point to platform would be used instead (Gattu et al, 1997; Pederson et al, 
2002). It has the advantage of eliminating the factor of swimming speed. However, 
according to my training protocol, the entrance for each trial might not be the 
same (mice are placed randomly at three different quadrants), which means, the 
shortest distance form the start point to the platform is different in each trial. In 
order to make a better comparison between two consecutive trials, the cumulative 
distance was replaced by SEI. The SEI is calculated according to the following 
formula 
Total distance of swimming path 
The linear distance from the start point to the platform 
The SEI score reflects how efficient the mouse finds the target platform. The 
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higher the SEI score, the poorer the mouse performs in finding the platform. 
4.2.6 Visual acuity test 
A visual acuity test was performed at the end of the experiment in order to assure 
that the animals did not have any visual defects. The mouse was allowed to have two 
trials to swim for a white platform that was above from water level. The mouse was 
generally able to find the platform with minimal effort and the swimming activities 
were recorded by the video camera during the second trial. 
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4.3 RESULTS 
4.3.1 Chronic crytotanshinone treatment does not cause hepatic damages to the 
mice 
The mice treating with cryptotanshinone (CT lOmg/kg/day, i.p.) for 10 days did 
not have any significant effect on the body weight compared with the controls (data not 
shown). In order to evaluate if CT treatment has any detrimental effect, the liver 
function tests on AST and ALT activities in plasma were examined. As shown in Figure 
3.2, there was no significant change in the level of AST and ALT enzyme activities in 
treated animals in comparison to the controls. Therefore, it is concluded that the drug 
was not toxic to the animal at lOmg/kg CT and is suitable for chronic usage. 
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Fig 3.2 Effect of chronic CT treatment on ALT and AST enzyme activities in mice: 
The male BALB/c mice in each group (n=8) were treated with CT or with vehicle only 
for 10 days. The animals were sacrificed and the plasma was collected as described in 
the Materials and Methods. Plasma ALT and AST levels were measured with the 
commercial kits. The p values were calculated by the t-test between CT treated and 
control group for A S T : 0.134，and p value for ALT set = 0.867. 
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4.3.2 Training Session 
In the training session, mice acquired the spatial memory and memorize the 
relative position of the hidden platform. This resulted in a general trend of decrease in 
escape latency throughout the 24 trails. In order to investigate the effect of CT on 
reducing the scopolamine-impairment of spatial memory, it is crucial to recruit the mice 
that have acquired the spatial memory during the training period and to exclude those 
that do not meet the required standard. Mice with average escape latency below 40s in 
the last 15 trials were selected. The first nine trials were not included for the analysis 
because these trials were given to let the mice to familiarize with the task. 
The escape latency decreased rapidly after the mice acquired visual clues and 
consolidated the memory on the location of the hidden platform. After the training 
session, five mice from the CT treated group and three mice from the control group 
were excluded from further analysis because they failed the selection criteria. Fig 3.3 
shows a 3D scatter plot of the escape latency on day 1 and day 5 of the selected mice 
performed in the different trials. Each spot represents the escape latency of a single trial. 
After 5 days of training, all mice showed a general trend in the reduction of the escape 
latency. Most of the spots on day 5 were at a region less than 20 sec. Some mice did not 
show any improvement in escape latency even after days of training. The reasons for 
their poor performance are not clear. Most of the poor performers developed the patterns 
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of behavior such as floating or kept swimming along the wall (thigmotaxis). Similar 
observation has previously been reported indicating that approximately 49% and 19% of 
performance variation (n=1400 mice) contributed by thigmotaxis and floating 
respectively (Wolfer et al, 1998). The authors suggested excluding the mice obtained 
poor task performance for drug efficacy evaluation. 
In addition to the escape latency, there are several parameters that were proposed to 
have a more accurate assessment of spatial memory retention: They are the parameters 
on (1) average time spent at target quadrant (%T) and (2) the average distance from 
target (platform) (AvgD) spent during swimming. An increase in %T and a decrease in 
AvgD after training session indicated that mouse has acquired spatial memory retention 
(Fig 3.4). 
Mice that were included for further analysis were randomly divided into two 
groups that were injected with CT or vehicle as control on day 3. The swimming trials 
continued after CT treatment. Fig 3.5 compares the escape latency between the two 
groups before and after training, there was no significant difference in training 
performance between the two groups of mice (they all have significant decrease in 
escape latency after training). 
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Fig 3.3 The 3-D graph showing the escape latency on day 1 and day 5 of training 
session in mice. Each black dot represents the escape latency of individual swimming 
trial on day 1 whereas each white dos represents the escape latency of individual 
training on day 5 (a) the mice (n=16) that have the mice that passed the selection criteria 
(b) mice (n=8) that performed poorly were excluded for the scopolamine resistance test. 
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Fig.3.4 Comparison of probe test results before and after training. The percentage of 
time spent in target quadrant (%T) (top panel) and the average distance from target 
(AvgD) (bottom panel) were scored in the first and last training. There was significant 
increase in %T and decrease in AvgD. The values are shown in mean 士 S.E.M.，with n= 
16. T h e p values were calculated by paired t-test, **• =p<0.001, ** =p<0.01 
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Fig 3.5 The 3-D graph showing the training data of the (a) CT-pretreated group and (b) 
control group on day 1 and day 5. Each spot represents the escape latency of an 
individual trial. Five training trials were performed each day. There were totally 7 mice 
in the CT group and 9 mice in the control group. P values were calculated by 
Mann-Whitney Rank Sum Test 
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4.3.3 Scopolamine ResistanceTest 
After watermaze training for five days, seven mice from CT treated group and nine 
mice from control group were selected for scopolamine-induced amnesia. 
In the first scopolamine resistance test on day 6, the result is summarized in Fig 3.6. 
Consistent with previous findings, scopolamine treatment significantly impaired the 
spatial memory clue previously acquired in the training session. Animals treated with 
scopolamine significant decreased the average time spent at the quadrant where the 
hidden platform was located (Fig 3.6a) and increase in the amount of time spent distant 
from the target (Fig 3.6b). This impairment appeared to be ameliorated in animals 
pretreated with 1 Omg/kg CT. 
In the second scopolamine resistance test on day 7, escape latency and SEI were 
used to assess the spatial memory retention. Table 3.1 shows the escape latency and SEI 
between two groups of mice before and after scopolamine injection. In the control group, 
all mice showed increase in escape latency after scopolamine injection, and nearly all 
mice had gain in SEI. In CT group, three out of seven mice showed an increase in 
escape latency and five out of seven mice showed increase in SEI. The average increase 
in escape latency and SEI of control group were 5-fold and 3-fold higher than those data 
obtained from the CT group. The results suggested that CT pretreatment could partially 
ameliorate the spatial memory impairment induced by scopolamine insult. 
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Fig 3.6 The results on the probe test of mice prior to and after 0.5mg/kg scopolamine 
injection on CT pretreated (n=7) or control group (n=9). (a) In the control group, after 
scopolamine injection, there is a significant decrease in the percentage of time spent in 
the target quadrant (**p<0.05). In the group pretreated with lOmg/kg CT, no significant 
difference in performance was found after scopolamine injection (p=0.578/ 
(b) Average distance from target calculated by the capture software also showed a 
similar trend. CT pretreated group did not show a significant increase in the average 
distance from target {p=0.156). Vehicle treated (control) group had a significant drop in 
performance (***p<0.005) caused by scopolamine. Each values are shown in mean 土 
S.E.M. The p values were calculated by the Signed-Rank test. 
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Table 3.1 A comparison of the escape latency and SEI between CT pretreated (a) and 
control group (b) after scopolamine-induced amnesia. Trials that showed an increase in 
escape latency and SEI are shaded in grey color, indicating the spatial memory loss by 
scopolamine treatment. In this study, three mice from CT group and all mice from 
control group showed an increase in escape latency after scopolamine injection. For SEI, 
five out of seven mice from CT group and eight out of nine mice from control group 
increased in SEI score after scopolamine injection. 
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4.3.4 Visual acuity test 
The visual acuity test, which is also called visible platform test, was performed on 
the last day. The performance in the visible platform test is affected by factors such as 
vision, swimming ability, and motivation to escape from water. Mice that did not swim 
a direct path to the visible platform in the visual acuity test would be considered failure 
to pass the visual acuity test. The test result showed that CT and scopolamine injection 
did not cause any visual impairment in all mice. 
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4.4 DISCUSSION 
In this study, mice administered with cryptotanshinone (CT, 10 mg/kg, i.p.) 
were found to have mild effect ameliorating the spatial impairment induced by 
scopolamine (0.5 mg/kg, i.p.) in a water maze task. The drug used in this study is 
relatively high comparing with other AChEIs. For example, previously studies usiing 
0.75 mg/kg rivastigmine and 0.05 mg/kg physostigmine injected subcutaneouly (s.c.) 
were found to successfully reverse the behavioral deficit elicited by 0.5 mg/kg 
scopolamine (i.p.) (Wang et. al, 2000). Likewise, donepezil (0.3 and 1.0 mg/kg, i.p.) 
and tacrine (3 and 5 mg/kg, i.p.) injections were able to reverse spatial impairment by 
0.4 mg/kg scopolamine (i.p.) (Chen et. al, 2002); Huperzine (0.1-0.4 mg/kg, s.c.) 
ameliorated 0.1 mg/kg scopolamine (i.p.) impairment (Ye et. al, 2000). The effective 
dose of these AChEI is about 1/10 of CT. Therefore, CT is regarded as a mild AChEI in 
vivo.. 
The use of AChEI on treating AD is common. However, patients have experienced 
many side-effects by taking these AChEIs. The side-effects include nausea, vomiting, 
diarrhea, dizziness, sleep disturbance, and in most cases, gastrointestinal upset. The 
side-effects are particularly severe while using strong AChEI such as tacrine and 
huperzine. Therefore, slow dose-escalation scheme is recommended when treating 
patients with AChEI (Racchi et. al, 2004). Mild AChEIs might give a better control in 
- 8 5 -
dose titration. Cholinergic side effects might be contributed by non-specific inhibition to 
BuChE, which is concentrated in red blood cells. 
As CT is a mild AChEI in vivo, with no observable toxicity in its treatment dose, 
has beenproven that it can enter the brain (Xie and Shen, 1983)，and shows low 
cross-inhibition to BuChE (Ho, 2003)，it has potential for further development as an 
anti-AD drug. 
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Chapter 5 General Discussion and Future Directions 
5.1 AOF, the potential GSK-3P inhibitor 
In conclusion, a cell model mimicking tau hyperphosphorylation by GSK-3 p was 
established in this study. The ethanol extract and the essential oil of AOF were found to 
contain active constituents that have potent inhibition of tau phoraphorylation mediated 
by GSK-3 曰 over-expression in COS-7 cells. From the analysis of GSK-3p activity, it 
would appear that the action is mediated through a direct inhibition of GSK-Sp, as 
demonstrated by in vitro GSK-Sp assay. AOF essential oil could also reduce GSK-3(3 
phosphorylation at Ser-9, which is known to be phosphorylated by protein kinase B 
(Akt kinase). Whether the AOF essential oil has a direct inhibitory effect on Akt is 
presently not known. Several GSK-3p inhibitors are ATP competitive compounds and 
also inhibit a wide range of other protein kinases (Alonso and Martinez, 2004). One 
limitation of the present study is that the specificity of AOF essential oil on GSK-3p 
activity has not been characterized. Comparison of the inhibitory profiles to other 
well-known kinases would be necessary in order to confirm that the inhibition is 
specific for GSK-3p. 
Another concern of the potential use of AOF as a drug is that whether the active 
component can get through the blood-brain barrier. The constituents of essential oil, 
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which contain mainly terprenes and small oxygenated organic molecules, the active 
component inside would have a high possibility that can enter the blood-brain barrier. 
In this study, lithium was used as a positive control for GSK-Sp inhibition. Lithium 
treatment can effectively inhibit tau phosphorylation by GSK-3P in cell cultures (Kelin 
and Melton, 1996). It is a direct GSK-3P inhibitor and has been widely used to study the 
putative role of GSK-3p. However, other than GSK-3P, lithium affects a wide range of 
enzymes. It is also a inhibitor of inositol monophosphatase (IMPase), inositol 
polyphosphate 1-phosphatase (IPPase), bisphosphate 3'-nucleosidase (BPntase), HAL2 
phosphatase and fructose 1,6-bisphosphatase (FBPase) (Pheil and Klein，2001). 
In future work, the active ingredient of AOF essential oil will be the further 
fractionated by silica gel column chromatography coupled to gas chromatography-mass 
spectrometry (Luo et al, 2001). By comparing the MS data of the active fraction, it is 
hoped that the active component of AOF could be identified. 
5.2 CT—theAChEI 
In this study, an in-house water maze system was set up to test the in vivo 
efficiency of the CT. Although the study suffered from the small number of animals for 
analysis, the present preliminary data suggest that CT has a mild protective effect on 
scopolamine-induced amnesia. In the future, the above experiment will be repeated with 
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increased number of mice in order to reduce individual variation and provide a better 
statistical analysis and a firm conclusion. 
Since 10 mg/kg CT does not produce toxic effect, it is possible to increase the CT 
treatment dose to see whether the effect of CT is dose-dependent. Treating mice with 
other known AChEI can be used to compare with CT. The existing AChEI that have 
been tested in water maze are Huperzine (Zhou J et al, 2001) and Galactamine (Sremek 
et al, 2000). Their effective dose seems to be lower than CT (lOmg/kg). Probably, it is 
due to the poor solubility of CT in its vehicle which in turn affects the absorption of the 
drug in the body. CT is lipophilic and it solves well in pure organic solvent, for example, 
N，N-dimethylacetylamide. Toxicity was an important determination of vehicle, 
therefore large portion of PEG and PBS were mixed with the organic solvent of CT, 
which resulted in the lowering of solubility. To determine the effective dose it is more 
important to know the amount of CT that entered the central nervous system (CNS), 
rather than how much is injected. In the future, two possible ways may be used to solve 
this problem (and they could be done in paraellel). The first is to evaluate the absorption 
of CT into the brain by HPLC analysis of brain tissue homogenate at different time 
points. In the meantime, another better vehicle should be found in which CT can be 
fully dissolved. 
Brain AChE activity of CT-treated mice could be assessed by Ellman assay. 
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Previous research has proven that prolonged treatment of AChEI can increase brain 
AChE activity in rodent (Zhou et al, 2001; Sremek et al, 2000) and results in an 
improvement in WMT performance. 
Apart from AChEI, this in-house water maze system may be used to test other 
potential AD drugs. Transgenic mice that exhibit AD pathological feature shows 
impairment in water maze task (Yamada and Nabeshima, 2000; Auld et al, 2002; 
Hemandex et al, 2002). In the future, this system can be used to test GSK-Sp inhibitor. 
Transgenic mice conditionally overexpressing GSK-3p is available as an animal model 
for the drug test. A less expensive animal model could be produced by intra-cerebral 
infusion of phosphatase lA or 2 A inhibitor to produce AD-like tau 
hyperphosphorylation in animal (Arendt et al, 1995), or by infusion of Ap fibrils into 
mouse brain (De Ferrair et al, 2003). These animal models show that cognitive 
impairment in water maze task and the impairment could be reversed by lithium 
treatment (De Ferrari et al, 2003). Also, treatment of lithium and GSK-Sp inhibitors 
successfully inhibit GSK-3p activity in rodent brains (O'Brien et al, 2004). 
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Al Reagents for SDS-PAGE 
Table la Solutions for preparing 10% resolving gels for SDS-PAGE 
Solution components 10 % Gel 
H2O 4 ml 
30% Acrylamide mix 3.3 ml 
l .SMTris (pH 8.8) 2.5 ml 
10% SDS 0.1ml 
10% APS 0.1 ml 
TEMED 4 \il 
Table lb Solutions for preparing 5% stacking gel for SDS-PAGE 
Solution components 5 % Stacking gel 
H2O 3.4 ml 
30% Acrylamide mix 0.83 ml 
1 M Tris (pH 6.8) 0.63 ml 
10% SDS 0.05 ml 
10% APS 0.05 ml 
TEMED 5 \x[ 
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30% Acrylamide mix 
Acrylamide 29 g/ 100 ml, N, N'-Methylenebisacrylamide 1 g/100 ml 
The solution was dissolved by warming at 37 filtered sterile and stored in darkness 
at 4 � C . 
Electrophoresis buffer for SDS-PAGE 
Tris-base 3.02 g/L, Glycine 18.8 g/L, 10% SDS lOml/L 
2x SDS sample loading buffer 
Tris-HCl (IM, pH 6.8) 2.5 ml, 10% SDS 10 ml, 
Bromophenol blue 0.25 % (w/v), Glycerol (99 %) 5 ml 
p-Mercaptoethanol (14.4 M) 2.5 ml 
The solution was made up to 25 ml by ddEbO 
Transfer buffer 
Glycing 2.9 g/L, Tris base 5.9 g/L, 
SDS 0.37 g/L, Methanol 200 ml/L 
- 1 0 4 -
TBS (lOx stock) 
Tris base 24.2 g/L, NaCl 80 g/L 
pH was adjucted to 7.6 
TBS 
100 ml of lOx TBS was added to 900 ml of distilled waqter. 1 ml of Tween 20 was 
added and stirred 
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A2 Reagents for competent cell preparation and DNA preparation 
LB medium 
Tryptone lOg, Yeast extract 5g, NaCl lOg 
The solution was made up to 1 L with ddH20 and autoclaved at 121 °C for 20 min 
LBA medium 
The LB medium was supplemented with filtered stock ampicillin solution (100 mg/ml) 
to a final concentration of 50 ng/ml in sterile condition. 
LB agar plate 
The powder mixture in preparing LB medium was supplemented with 1.5 % (w/v) 
bacto-agar. The solution (-30 ml) was poured to a 90 mm plate and cooled at room 
temperature until it was hardened. The plates were inverted and stored at 4 
LBA agar plate 
The procedures were the same as preparing LB agar plate except ampicillin (at a 
final concentration of 50 |ig/ml) was supplemented to the hand-hot LB agar solution 
before pouring onto plates. 
- 1 0 6 -
m 
RF 1 
Rn CI 12g/L Ca CI2.2H2O 11 g/L 
Mn CI2.4H2O 9.9 g/L Glycerol 15% 
KAc 3 g/L 
The solution was adjusted to pH 5.8 with NaOH and was filtered sterilized. 
RF2 
MOPS 2.09 g/L Rb CI 1.2 g/L 
Ca CI2 .2H2O 11 g/L Glycerol 15 % 
The solution was adjusted to pH 6.8 with NaOH and was filtered sterilize 
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A3 Solution components provided by QIAGEN Plasmid Maxipreps kit 
PI P2 P3 
Tris-base 6.06 g/L NaOH 8 g/L KAc (pH 4.8) 250.06 g/L 
Na2EDTA 3.36 g/L SDS 1 % 
RNase 100 |ig/ml 
QBT QC QF 
NaCl 43.83 g/L 73.05 g/L 87.66 g/L 
MOPS 10.47 g/L 10.47 g/L 10.47 g/L 
Ethanol 15% 15% 15% 
Triton X-100 0.15 % Nil nil 
Adjust to pH 7 7 not necessary 
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A4 Reagents and medium for cell culture 
IxPBS 
NaP04 (pH 7.2) 10 mM，NaCl 0.15 M 
DMEM medium for COS-7 cells 
10% Fetal Bovine Serum 50 ml, 1% Penicillin-Streptomycin 5 ml, 
85% DMEM 450 ml 
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A5 Reagents for kinase assay 
Protein sample lysis buffer (applicable to both Western analysis and kinase assay) 
Hepes (pH 7.4) 20mM sodium orthovanadate 1 mM 
EGTA 2 mM p-glycerophosphate 50 mM 
Triton X-100 1 % PMSF 350 |Lig/ml 
Glycerol 10% Pepstatin 1 |ig/ml 
DTT 1 mM Aprotinin 5 fig/ml 
Leupeptin 40 |Lig/ml 
The solution was freshly prepared before used. 
50 % slurry protein A-sepharose beads 
The beads were washed with PBS three times. Then the beads were made up to 50 % 
(v/v) in fresh lysis buffer. 
Wash buffer I Wash buffer II 
Tris-HCl pH 7.6 100 mM Hepes pH 7.5 25 mM 
Triton X-100 0.1 % Triton X-100 0.2 % 
DTT 1 mM EDTA-Na2 1 mM 
- 1 1 0 -
Kinase reaction buffer 




Orthovanadate 0.1 mM 
DTT 2mM 
- I l l -
A6 Raw data of figures 
Chapter 2 
Fig 2.3a The cytotoxicity test of the AOFl on COS-7 
AOFl \ig/m\\ % viability 
320 95.00 80.50 74.00 
200 103.00 89.00 85.00 
160 104.50 112.50 106.50 
80 110.00 120.50 104.50 
40 104.00 105.00 105.50 
20 103.50 115.00 97.50 
0 100.00 100.00 100.00 
Fig 2.3b The cytotoxicity test of the A0F2 on COS-7 
A0F2 % viability 
320 23.14 22.47 23.80 
160 62.50 67.95 86.04 
80 90.82 104.65 106.52 
40 85.11 112.00 97.34 
20 105.45 106.25 106.78 
10 118.09 115.82 114.36 
0 100.00 100.00 100.00 
Fig 2.6a The cytotoxicity test of the A0F3 on COS-7 cells 
A0F3 % viability 
640 77.74 80.92 
320 93.20 81.69 81.69 
200 120.39 104.93 104.93 
160 99.34 113.93 113.93 
80 109.54 92.32 92.32 
40 116.12 99.78 99.78 
20 108.11 103.84 103.84 
0 100.00 100.00 100.00 
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Fig 2.6b The cytotoxicity test of the A0F4 on COS-7 cells 
A0F3 % viability 
640 2 1 ^ 
320 15.96 13.71 20.46 
160 44.81 52.17 52.58 
80 68.75 81.94 76.32 
40 78.26 88.29 94.02 
20 101.48 86.96 90.43 
10 96.37 95.75 81.43 
5 102.51 101.28 103.94 
0 100.00 100.00 100.00 
Fig 2.8 Cytotoxicity test of A0F5 on COS-7 
i 
A0F5 i^g/mll % viability “ 
200 38.54 33.03 34.03 
100 27.03 26.78 27.28 
50 46.55 53.55 35.29 
25 73.82 68.32 66.07 
17 87.09 79.83 85.09 
13 87.59 82.83 78.08 
8 86.84 91.34 77.33 
0 100.00 100.00 100.00 
Fig 2.10 Effect of A0F5 treatment on kinase activity of GSK-3p in COS-7 cells 
optical density % of control 
control m 100.00 
20mM LiCl 184 96.34 
30mM LiCl 147 76.96 
10 mg/ml AOF(oil) 170 89.01 
16 mg/ml AOF(oil) 129 67.54 
21 mg/ml AOF(oil) ^ 79.58 
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Chapter 3 
Fig 3.2 Effect of CT on the liver function test: plasma ALT and AST level 
AST (U/L) ALT (U/L) 
CT-treated Control CT-treated Control 
66.17 63.89 41.78 59.83 
64.33 108.22 32.89 14.89 
137.44 88.56 10.78 10.00 
72.44 127.56 -2.44 32.67 
95.44 68.44 28.78 -14.11 
49.89 101.67 9.00 18.22 
50.67 150.56 23.00 18.44 
-58.58 15.78 6.78 22.44 
Fig 3.4a 3-D graph showing the training data of the selected on day 1 and day 5 
Escape Latency /s 
Dayl 17 40 2 1 9 0 90 90 24 90 42 2 3 1 5 9 0 1 3 
90 18 90 20 90 40 90 2 90 21 90 29 28 
40 21 7 5 90 26 90 5 46 34 46 90 30 
5 4 57 5 85 90 31 90 23 12 56 90 17 
17 35 90 90 60 90 4 90 90 12 25 90 
D ^ 7 S 1 9 5 5 9 0 8 1 4 35 2 5 8 40 90 
19 19 20 5 28 12 8 6 21 16 18 12 4 
10 20 15 6 4 55 3 22 21 7 8 41 9 
30 17 6 8 16 10 5 5 51 6 10 8 13 
13 16 36 9 7 5 12 12 16 5 7 29 8 
12 6 3 11 12 9 13 15 4 11 33 6 6 
16 10 42 
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Fig 3.4b 3-D graph showing the training data of the excluded mice on day 1 and day 5 
Escap Latency /s 
Day 1 1 2 % 4 5 2 S ^ ^ % % 3 ^ % ^ 
90 5 90 90 37 90 60 2 90 90 12 37 90 
9 90 20 4 35 90 
Day 5 ^ % 7 〒 ？ > % % % % 8 ^ ~ % ^ % 
90 45 31 34 30 90 63 90 90 28 35 6 8 
36 30 90 90 90 29 1 38 49 49 90 90 90 
21 
Fig.3.5a Comparison of probe test results (Percentage of time spent on target quadrant) 
before and after training 
Percentrage of time spent in 
target quadrant 
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Fig.3.5b Comparison of probe test results (Average distant from target) before and after 
training 




















Fig 3.6b 3-D graph showing the training data of the CT-pretreated group on day 1 and 
day 5 
Escape Latency /s 
D ^ 1 7 1 4 % n % 1 3 6 M 2 5 ^ 1 3 ^ ^ 
15 28 31 48 7 38 25 20 13 28 35 13 65 
90 17 13 12 90 6 90 45 41 
D ^ Y s ^ ^ 4 5 % ^ 4 1 7 5 3 8 1 2 
8 16 24 23 14 14 47 25 38 15 5 14 14 
I 47 6 38 13 24 45 9 13 17 
- 1 1 6 -
^ 
Fig 3.6b 3-D graph showing the training data of the CT-pretreated group and control 
group on day 3 and day 5 
Escape Latency Is 
D ^ ^ ^ 1 9 ^ 4 8 8 9 5 % 1 0 1 6 4 8 W 
24 38 90 21 20 56 16 90 26 38 59 28 88 
40 15 14 25 9 22 18 5 60 18 90 49 35 
6 36 8 4 55 14 
Day5 ~ ~ [ 4 2 0 4 0 6 n M 5 Y s 4 7 5 7 ^ 4 
60 14 11 5 13 9 17 54 7 19 55 17 14 
90 6 22 35 3 10 22 19 30 15 42 26 90 
18 56 46 20 90 42 
Fig 3.7a Probe test result (% of time spent in target quadrant) before and after 
scopolamine injection on CT pretreated or control group 
CT-treated Control 
before after before after 
injection injection injection injection 
FmO l u T 
23.55 16.08 18.29 12.11 
27.13 10.87 25.00 8.01 
19.76 7.90 40.80 16.17 
44.63 23.48 22.74 10.68 
22.30 39.00 41.61 8.47 
19.60 17.00 30.68 15.66 
34.27 15.43 
I9.73I 25.31 
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Fig 3.7b Probe test result (average distance from target) before and after scopolamine 
injection on CT pretreated or control groups 
CT-treated Control — 
before after before after 
injection injection injection injection 
70.88 62.01 72.78 92.86 
67.64 81.78 81.29 86.72 
70.44 81.92 77.74 93.22 
77.05 89.55 57.81 80.38 
56.58 75.54 85.56 91.15 
74.3 64.09 65.23 87.17 
74.01 74.6 62.65 79.42 
63.45 80.79 
I 62.651 68.56 
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A7 Plasmid map of PCI-neo 
BgiW 
X CMVI.E. l -P^I 
f ^ / Enhancer/Promoter N A ^ 
/ / 二 = 
/ L^r p f l -睡 S^AOJ^^Wk 競 丨 溫 2 
^ VectM * \ A'faal 1114 
, (5472bp) r S \ Sb{ I 1120 
I \ ^ / , / \ AccI 1121 
\ \ t l o n / / / \ Smal 1127 
W \ _ 1131 
\ Synth明c SV40 Enhancer/ J v / \ T3 T 
\ PoWA) Early P r o m o t e j / " ^ ^ 
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